

# The Turkish Journal of Ear Nose and Throat

Volume 31, Number 2 / June 2021

DİZİNLER / INDEXING AND ABSTRACTING

TÜBİTAK-ULAKBİM TR Index

**OWNER**

Prof. Dr. Tufan TÜKEK

Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

**RESPONSIBLE MANAGER**

Prof. Dr. Bülent BAYRAKTAR

Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

**CORRESPONDENCE ADDRESS**

Istanbul University, Istanbul Faculty of Medicine Deanery, Publication Commission

Turgut Özal Caddesi 34093 Çapa, Fatih, Istanbul, Turkey

Phone: +90 (212) 414 21 61

E-mail: tr-ent@istanbul.edu.tr

<https://dergipark.org.tr/tr/pub/trent>

<https://iupress.istanbul.edu.tr/tr/journal/tr-ent/home>

**PUBLISHER**

Istanbul University Press

Istanbul University Central Campus,

34452 Beyazit, Fatih / Istanbul, Turkey

Phone: +90 (212) 440 00 00

---

Dergide yer alan yazılardan ve aktarılan görüşlerden yazarlar sorumludur.  
Authors bear responsibility for the content of their published articles.

Yayın dili İngilizce'dir.

The publication language of the journal is English.

Mart, Haziran, Eylül ve Aralık aylarında, yılda dört sayı olarak yayımlanan uluslararası, hakemli, açık erişimli ve bilimsel bir dergidir.  
This is a scholarly, international, peer-reviewed and open-access journal published quarterly in March, June, September and December.

---

**Publication Type:** Periodical

---

## EDITORIAL MANAGEMENT BOARD

### EDITOR-IN-CHIEF

Prof. İsmet ASLAN – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [ismetaslan@istanbul.edu.tr](mailto:ismetaslan@istanbul.edu.tr)

### CO-EDITOR-IN-CHIEF

Prof. Kadir Serkan ORHAN – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [ksorhan@istanbul.edu.tr](mailto:ksorhan@istanbul.edu.tr)

Assoc. Prof. Bora BAŞARAN – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [bbasaran@istanbul.edu.tr](mailto:bbasaran@istanbul.edu.tr)

### SECTION EDITORS

#### Otology & Neurootology Section Editors

Assoc. Prof. Beldan POLAT – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [beldanp@istanbul.edu.tr](mailto:beldanp@istanbul.edu.tr)

Assoc. Prof. Mehmet ÇELİK – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [mehmetcelik@istanbul.edu.tr](mailto:mehmetcelik@istanbul.edu.tr)

Uzman Dr. Said SÖNMEZ – Van Training and Research Hospital, Department of Otorhinolaryngology, Van, Turkey – [dr.saidsonmez@gmail.com](mailto:dr.saidsonmez@gmail.com)

#### Rhinology Section Editors

Prof. Nesil KELEŞ – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [nkeles@istanbul.edu.tr](mailto:nkeles@istanbul.edu.tr)

Assoc. Prof. Şenol ÇOMOĞLU – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [senol.comoglu@istanbul.edu.tr](mailto:senol.comoglu@istanbul.edu.tr)

Assist. Prof. Levent AYDEMİR – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [levent.aydemir@istanbul.edu.tr](mailto:levent.aydemir@istanbul.edu.tr)

#### Head&Neck Section Editors

Assoc. Prof. Murat ULUSAN – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [mulusan@istanbul.edu.tr](mailto:mulusan@istanbul.edu.tr)

Assist. Prof. Cömert ŞEN – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [comert.sen@istanbul.edu.tr](mailto:comert.sen@istanbul.edu.tr)

#### General ORL Section Editors

Assoc. Prof. Selçuk GÜNEŞ – Memorial Hospital, Department of Otorhinolaryngology, Istanbul, Turkey – [drselcukgunes@gmail.com](mailto:drselcukgunes@gmail.com)

Assist. Prof. Burak KARABULLUT – İstanbul Kartal Dr. Lutfi Kırdar City Hospital, Department of Otorhinolaryngology, Istanbul, Turkey – [drburakkara@yahoo.com](mailto:drburakkara@yahoo.com)

#### Facial Plastic Surgery Section Editors

Prof. Yusufhan SÜOĞLU – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [suoglu@istanbul.edu.tr](mailto:suoglu@istanbul.edu.tr)

Dr. Deniz KANLIADA – Special Clinic, Department of Otorhinolaryngology, London, England – [drdeniz.ent@gmail.com](mailto:drdeniz.ent@gmail.com)

Dr. Caner KEŞİMLİ – Istinye University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [canerkesimli@gmail.com](mailto:canerkesimli@gmail.com)

#### Laryngology Section Editors

Assist. Prof. Necati ENVER – Marmara University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [necatienv@gmail.com](mailto:necatienv@gmail.com)

Res. Assist. Can DORUK – Tekirdağ City Hospital, Department of Otorhinolaryngology, Istanbul, Turkey – [can.doruk@istanbul.edu.tr](mailto:can.doruk@istanbul.edu.tr)

### PUBLICITY MANAGER

Assoc. Prof. Mehmet ÇELİK – Istanbul University, Faculty of Medicine, Department of Otorhinolaryngology, Istanbul, Turkey – [mehmetcelik@istanbul.edu.tr](mailto:mehmetcelik@istanbul.edu.tr)

### LANGUAGE EDITORS

Elizabeth Mary EARL – Istanbul University, Department of Foreign Languages, Istanbul, Turkey – [alan.newson@istanbul.edu.tr](mailto:alan.newson@istanbul.edu.tr)

Alan James NEWSON – Istanbul University, Department of Foreign Languages, Istanbul, Turkey – [elizabeth.earl@istanbul.edu.tr](mailto:elizabeth.earl@istanbul.edu.tr)

### EDITORIAL ASSISTANT

Birgül TAŞTEMİR – Istanbul University, Istanbul, Turkey – [tr-ent@istanbul.edu.tr](mailto:tr-ent@istanbul.edu.tr)

## EDITORIAL ADVISORY BOARD

- Prof. Shakeel SAEED – University Collage London Hospital, Department of Otorhinolaryngology, London, United-Kingdom – [shakeel.saeed@ucl.ac.uk](mailto:shakeel.saeed@ucl.ac.uk)
- Prof. Vedat TOPSAKAL – Universitair Ziekenhuis Brussel, Department of Otorhinolaryngology, Brussels, Belgium – [Vedat.Topsakal@uza.be](mailto:Vedat.Topsakal@uza.be)
- Assoc. Prof. Barış KARAKULLUKÇU – Netherlands Cancer Institute, Department of Otorhinolaryngology, Amsterdam, Netherlands – [b.karakullukcu@nki.nl](mailto:b.karakullukcu@nki.nl)
- Prof. Cüneyt ALPER – University of Pittsburgh, Department of Otorhinolaryngology, Pittsburg, United-States – [cuneyt.alper@chp.edu](mailto:cuneyt.alper@chp.edu)
- Assoc. Prof. Sancak YÜKSEL – Texas University, Department of Otorhinolaryngology, Texas, United-States – [Sancak.Yuksel@uth.tmc.edu](mailto:Sancak.Yuksel@uth.tmc.edu)
- Prof. Mehmet MANİSALI – St. George’s Hospital, Department of Otorhinolaryngology, London, United-Kingdom – [M.manisali@mac.com](mailto:M.manisali@mac.com)
- Prof. Emre Vural – UAMS Health, Arkansas, Department of Otorhinolaryngology, United-States – [vuralemreahmet@uams.edu](mailto:vuralemreahmet@uams.edu)
- Prof. Jaydip RAY, Sheffield Children Hospital, Department of Otorhinolaryngology, Sheffield, United-Kingdom – [jaydip.ray@sht.nhs.uk](mailto:jaydip.ray@sht.nhs.uk)
- Prof. Ulugbek KHASANOV – Tashkent Medical Academy, Department of Otorhinolaryngology, Tashkent, Uzbekistan – [ukhasanov@yahoo.com](mailto:ukhasanov@yahoo.com)
- Specialist Abdulhaliq EMİN – Hawler Medical Universit (HMU) Collage of Medicine, Department of Otorhinolaryngology, Erbil, Iraq  
– [abdulhaliq.kerim@hmu.edu.led](mailto:abdulhaliq.kerim@hmu.edu.led)
- Prof. Yahya GÜLDİKEN – İstanbul University, Faculty of Medicine, Department of Otorhinolaryngology, İstanbul, Turkey – [yahyaguldiken@hotmail.com](mailto:yahyaguldiken@hotmail.com)
- Prof. Çağatay OYSU – Marmara University, Faculty of Medicine, Department of Otorhinolaryngology, İstanbul, Turkey – [coysu@hotmail.com](mailto:coysu@hotmail.com)
- Prof. Orhan ÖZTURAN – Bezm-î Âlem Vakıf University, Faculty of Medicine, Department of Otorhinolaryngology, İstanbul, Turkey – [orhanent@yahoo.com](mailto:orhanent@yahoo.com)
- Prof. Arif ULUBİL – Private Practice, İstanbul, Turkey – [aclubil@yahoo.com](mailto:aclubil@yahoo.com)
- Prof. Murat ÜNAL – Liv Ulus Hospital, Department of Otorhinolaryngology İstanbul, Turkey – [drmunal@gmail.com](mailto:drmunal@gmail.com)
- Prof. Bayram VEYSİLLER – Private Practice, İstanbul, Turkey – [bayramveyseller@gmail.com](mailto:bayramveyseller@gmail.com)
- Prof. Kemal DEĞER – İstanbul University, Faculty of Medicine, Department of Otorhinolaryngology, İstanbul, Turkey – [kdeger@gmail.com](mailto:kdeger@gmail.com)
- Prof. Erkan KIYAK – İstanbul University, Faculty of Medicine, Department of Otorhinolaryngology, İstanbul, Turkey – [ekiyak@istanbul.edu.tr](mailto:ekiyak@istanbul.edu.tr)
- Prof. Enis Alpin GÜNERİ – Dokuz Eylül University, Faculty of Medicine, Department of Otorhinolaryngology, İzmir, Turkey – [alpin.guneri@deu.edu.tr](mailto:alpin.guneri@deu.edu.tr)

## CONTENTS

---

### RESEARCH ARTICLES

- 25** Comparison of Subjective and Objective Success of Septoplasty in Patients with Nasal Septum Deviation: A Before and After Study  
**Aytekin Uzer, Erhan Demirhan**
- 34** Audiovestibular Manifestations in Autoimmune Disorders: A Case Clinical Control Study in Celiac Patients  
**Nesrettin Fatih Turgut, Dilek Gülmez, Hasan Ahmet Özdoğan**
- 39** Do Tumor Board Recommendations Influence the Decisions of Clinicians in Planning the Treatment of Head and Neck Cancers?  
**Gökhan Akgül, Nesrettin Fatih Turgut, Mehmet Dursun Mehel, Serap Aydođdu, Abdulkadir Özgür**
- 45** Validation of the Turkish Translation of the Facial Clinimetric Evaluation Scale in Patients with Peripheral Facial Paralysis  
**Ađah Yeniçeri, FakiH Cihat Eravcı, Mücahit Yalçın, Hakan Tutar**
- ### CASE REPORT
- 51** Nasal Reconstruction Using Tissue Expander and Modified Paramedian Forehead Flap Supported by Cartilage Graft  
**Pauline Yap, Nurul Syazana Mohamad Shah, Arman Zaharil Mat Saad, Wan Azman Wan Sulaiman, Siti Fatimah Noor Mat Johar**



# Comparison of Subjective and Objective Success of Septoplasty in Patients with Nasal Septum Deviation: A Before and After Study

Aytekin Uzer<sup>1,3</sup> , Erhan Demirhan<sup>2,3</sup> 

<sup>1</sup>Dr. Aytekin Uzer's Special Clinic, Istanbul, Turkey

<sup>2</sup>VoicENT – ENT & Voice Disorder Center, Izmir, Turkey

<sup>3</sup>Health Sciences University Tepecik Training and Research Hospital Ear Nose Throat Diseases and Head & Neck Surgery Clinic, Izmir, Turkey

ORCID ID: A.U. 0000-0002-4342-6066; E.D. 0000-0001-8871-0821

**Citation:** Uzer A, Demirhan E. Comparison of subjective and objective success of septoplasty in patients with nasal septum deviation: a before and after study. Tr-ENT 2021;31(2):25-33. <https://doi.org/10.26650/Tr-ENT.2021.40412>

## ABSTRACT

**Objective:** Aim of the study is to evaluate the subjective outcomes and objective outcomes postoperatively and investigate correlations between these measurements.

**Material and Methods:** This prospective before and after surgical study was conducted with patients admitted with symptomatic nasal septum deviation (NSD) and who underwent Cottle's septoplasty. Morphometric diameters of the nasal cavity were measured using a multi-detector computed tomography. Preoperative and postoperative one-month Nasal Obstruction Symptom Evaluation Scale (NOSE) score, acoustic rhinometry (AR), and anterior active rhinomanometry (AAR) measurements were used to evaluate the success of surgery. The correlations between these measurements were also evaluated.

**Results:** The study population consisted of 30 patients, including 19 males and 11 females, with a median age of 27.5 years. There was a statistically significant difference between pre and postoperative NOSE scores, with a mean difference of 53.17 points ( $p < 0.001$ ). There were statistically significant differences between pre and postoperative AR parameters of both the deviated side (DS) and non-deviated side (NDS) of the nose both before and after decongestion. There were statistically significant improvements in all postoperative airflow and airway resistance parameters of the DS of the nose before decongestion when compared to preoperative measurements. There were moderate to large positive correlations between morphometric diameters and differences in NOSE score. Further, there were several statistically significant correlations between differences in AR and AAR measurements and differences in NOSE score.

**Conclusion:** Our findings showed that the objective measurements are strongly correlated with the NOSE score.

**Keywords:** Pyriform aperture, choana, nasal septum deviation, septoplasty

## INTRODUCTION

Nasal obstruction is one of the most common complaints in the rhinology clinical practice (1, 2). Although conservative non-surgical medical therapy is the first option for the treatment of nasal obstruction, it is usually unsuccessful in relieving complaints of nasal obstruction which resulted from a deviated or deformed nasal septum (3). Septoplasty is widely performed to correct the septal deviation or deformity, and therefore is one of the most commonly performed surgical procedures in otorhinolaryngology (4-6).

Septoplasty is the surgical correction of the deviated or deformed nasal septum, the first examples of which date back to ancient Egypt (7). Nowadays, a variety of techniques are performed by surgeons in septoplasty operations; the types of nasal septal deviation (NSD) and surgeon's preferences are important to decide which technique to be applied (8, 9). Cottle's septoplasty with a hemitransfixion incision is one of the most frequently used techniques in the world (9).

In clinical practice, there are several diagnostic tools including subjective and objective measurements (10). Subjective

**Corresponding Author:** Aytekin Uzer **E-mail:** [aytekinuzer@gmail.com](mailto:aytekinuzer@gmail.com)

**Submitted:** 31.03.2021 • **Accepted:** 02.06.2021



This work is licensed under Creative Commons Attribution-NonCommercial 4.0 International License.



measurements use validated questionnaires and try to determine the level of the patient's discomfort before surgery and also the relief of the patient's symptoms after surgery (2). Although subjective measurements have been used widely in clinical practice, their subjective nature is an ongoing problem, especially in long-term follow-up assessments (11, 12).

Objective measurements use several analysis methods, examine the deformed anatomy of the nose, measure the degree of nasal obstruction and evaluate nasal resistance (10). These methods provide detailed objective measurements before the surgery and guide the surgeons to decide the most convenient surgical technique (2). They are also repeated after surgery to show the effectiveness of the applied surgery, such as the correction of an anatomical part or obtaining openness (lack of obstruction) of a bodily passage (6). However, several studies have demonstrated that favorable postoperative measurements did not result in the patient's satisfaction (10). Therefore, there is a long and still ongoing conflict in the reliability of objective measurements of nasal patency and patient satisfaction (2).

This study aims to compare subjective outcomes such as the Nasal Obstruction Symptom Evaluation Scale (NOSE) score and objective outcomes such as acoustic rhinometry (AR) and anterior active rhinomanometry (AAR) measurements of Cottle's septoplasty in patients with NSD, and to evaluate the correlations between morphometric measurements and the difference in those subjective and objective outcomes.

## MATERIAL AND METHODS

### Design and setting

This prospective before and after surgical study was conducted with patients admitted with symptomatic nasal septum deviation (NSD) and underwent septoplasty in the University of Health Sciences Izmir Tepecik Training and Research Hospital between October 2016 and November 2016. Ethical approval was obtained from Izmir Tepecik Training and Research Hospital Ethics Committee (Approval date:18/08/2016, No:22), and written informed consent was obtained from all patients included in the study after detailed information about the study was given.

### Patients

Patients between the ages of 18-45 who presented complaints of nasal obstruction, difficulty in breathing through the nose and were diagnosed with NSD after physical examination, paranasal endoscopy, and paranasal computed tomography, were evaluated for eligibility. The patients with additional nasal or paranasal pathology, history of previous nasal or paranasal surgery, craniofacial anomaly, sinonasal malignancy, adenoid hypertrophy, nasal valve collapse, additional lower and upper respiratory pathology, cardiovascular or neurological pathology were excluded from the study.

### Surgical procedure

All patients underwent Cottle's septoplasty by a 3-years experienced surgeon under general or local anesthesia. A

hemitransfixion incision was performed, and the deviated septal portion was excised after elevating the mucoperichondrium and mucoperiosteum. After surgery, a nasal packing was applied and removed on the second postoperative day. All patients were prescribed postoperative antibiotics, analgesics, and decongestants. Patients were followed-up with outpatient visits at the postoperative first and second week and first month.


### Variables and outcomes

Patients' demographics and clinical features were recorded. The type of NSD was classified according to the Mladina classification using nasal endoscopic evaluation (Karl Storz Image 1 HUB HD camera system H3-Z Head, Germany) of the patients (13).

A multi-detector computed tomography (MDCT) (Siemens SOMATOM Definition AS 128 Slice CT scan, Germany) was used to exclude paranasal sinus pathologies preoperatively and to do morphometric measurements. The morphometric diameters were measured in millimeters (mm) based on a Turkish anatomic study by Aksu et al. (14). The morphometric variables were: (1) piriform aperture height, (PAH) which was defined as the distance between the rhinion and the anterior nasal spine; (2) piriform aperture width, (PAW) which was defined as the widest distance between the left and right bone margin on the transverse plane of pyriform aperture; (3) upper anterior face height, (UAFH) which was defined as the distance between nasion and anterior nasal spine; (4) choana height, (CH) which was defined as the distance between the furthest points on the vertical midline; (5) choana width, (CW) which was defined as the distance between the furthest points on the horizontal midline; (6) airway length, (AL) which was defined as the distance between the anterior nasal spine and the posterior nasal spine; and (7) upper palate width, (UPW) which was defined as the distance between the junction of the jugal alveolaria of the first and second molar teeth (Figure 1).

There are three primary outcomes of the study. These are the Nasal Obstruction Symptom Evaluation Scale (NOSE) score, acoustic rhinometry (AR) measurements, and anterior active rhinomanometry (AAR) measurements. Preoperative and postoperative one-month measurements were compared to evaluate the success of the surgery. Also, the correlation between the morphometric measurements, the differences (as an effect size) in AR and AAR parameters between pre and postoperative measurements, and the difference between pre and postoperative NOSE scores were evaluated.

AR (Rhinoscan®V2.6) and AAR (RhinoStream®v2.1) measurements were performed using the SRE 2000 Rhinometer before and one month after surgery, (RhinoMetrics, Lyngby, Denmark) following the recommendations of the International Rhinology Society and the European Rhinology Society in 2000 and 2005 (15, 16). The measurements were made on both the deviated side (DS) and non-deviated side (NDS) of the nose before nasal decongestion (BD) and after nasal decongestion (AD). AD parameters were measured 30 minutes after applying 0.01% xylometazoline HCL to both nostrils.



**Figure 1** shows the morphometric measurements of a patient with right-sided nasal septal deviation.

a) piriform aperture height of 29.75 mm, b) piriform aperture width of 20.98 mm, c) deviated side choana width of 12.31 mm and non-deviated side choana width of 14.01 mm, d) non-deviated choana height of 21.98 mm, e) deviated side choana height of 20.79 mm, f) airway length of 53.98 mm, g) upper anterior face height of 49.21 mm, and h) upper palate width of 55.65 mm.

The variables of the AR were: (1) the first minimal cross-sectional area (MCA1), which was the narrowest cross-sectional area ( $\text{cm}^2$ ) at a distance of 0-2.2 cm from the nostril; (2) the second minimal cross-sectional area 2 (MCA2), which was the narrowest cross-sectional area ( $\text{cm}^2$ ) at a distance of 2.2-5.4 cm from the nostril (3) the first volume (Vol1) of one side of the nasal cavity, which was the unilateral volume ( $\text{cm}^3$ ) of the nasal cavity between the nostril and 2.2 cm into the cavity; (4) the second volume (Vol2) of one side of the nasal cavity, which was the unilateral volume ( $\text{cm}^3$ ) of the nasal cavity between 2.2 to 5.4 cm from the nostril; (5) total volume of one side of the nasal cavity (tVol), which was the sum of Vol1 and Vol2; and (6) Total volume of two sides of the nasal cavity (TVol).

The AAR parameters were: (1) inspiration airflow of one side of the nasal cavity ( $\text{Flow}_{\text{ins}}$ ); (2) expiration airflow of one side of the nasal cavity ( $\text{Flow}_{\text{ex}}$ ); (3) total airflow of one side of the nasal cavity (tFlow) which was the sum of  $\text{Flow}_{\text{ins}}$  and  $\text{Flow}_{\text{ex}}$ ; (4) Total airflow of two sides of the nasal cavity (TFlow); (5) inspiration airway resistance of one side of the nasal cavity ( $\text{AR}_{\text{ins}}$ ); (6) expiration airway resistance of one side of the nasal cavity ( $\text{AR}_{\text{ex}}$ ); (7) total airway resistance of one side of the nasal cavity (tAR) which was the sum of  $\text{AR}_{\text{ins}}$  and  $\text{AR}_{\text{ex}}$ ; and (8) Total airway resistance of two sides of the nasal cavity (TAR).

### Statistical analysis

Statistical analysis was performed using SPSS 22.0 (IBM Corporation, Armonk, New York, United States). Descriptive statistics were presented as median with interquartile range (IQR) for non-normal distributed numeric variables, and frequency (n) with percentage (%) for categorical variables. The descriptive statistics of pre and postoperative numerical measurements and the differences between those two measurements were presented as mean with 95% confidence interval (95% CI). A Related-Samples Wilcoxon Signed Rank Test was used for comparing pre and postoperative numerical

measurements. The Spearman's Rank Order Correlation was used for evaluating the correlation between anatomical measurements, differences in functional measurements, and differences in NOSE scores before and after surgery. A *p*-value less than 0.05 was considered as the statistically significant level.

### RESULTS

Although 37 patients were enrolled in the study, 7 patients were excluded from the study due to the development of septal perforation in 2 patients, nasal synechia in 1 patient, inadequacy of the surgery in 1 patient, inappropriate MDCT images in 1 patient, and 2 patients not coming for a control visit during the follow-up period. Finally, the study population consisted of 30 patients, including 19 males and 11 females, with a median age of 27.5 years. Of the patients, 21 (70.0%) had right-sided deviation and 9 had left-sided deviation, and most of the patients (60.0%) were classified as type 7 according to the Mladina classification. The second most common type was type 2 with a percentage of 16.7. The median PAH was 33.94 mm, the median PAW was 21.25 mm, the median UAFH was 53.25 mm, the median CH of the deviated side of the nose was 23.62 mm, the median CH of the non-deviated side of the nose was 23.33 mm, the median CW of the deviated side of the nose was 13.66 mm, the median CW of the non-deviated side of the nose was 13.60 mm, the median AL was 53.39 mm, and the median UPW was 55.57 mm (Table 1).

Table 2 presents the comparison of the pre and postoperative NOSE scale scores of the patients. There was a statistically significant difference between pre and postoperative NOSE scores with a mean difference of 53.17 points ( $p < 0.001$ ).

Table 3 shows the comparison of the pre and postoperative acoustic rhinometry parameters of the patients. Except for the MCA2 measurements of the non-deviated side of the nose

**Table 1: Demographics, clinical features and nasal morphometric measurements of the patients**

Characteristics (n=30)		
Age (years), Median (IQR)		27.50 (24.75-35.00)
Sex, n (%)	Female	11 (36.7)
	Male	19 (63.3)
Deviation side, n (%)	Right	21 (70.0)
	Left	9 (30.0)
Mladina classification, n (%)	Type 1	3 (10.0)
	Type 2	5 (16.7)
	Type 3	1 (3.3)
	Type 4	1 (3.3)
	Type 5	1 (3.3)
	Type 6	1 (3.3)
	Type 7	18 (60.0)
PAH (mm), Median (IQR)		33.94 (30.98-35.25)
PAW (mm), Median (IQR)		21.25 (20.06-22.96)
UAFH (mm), Median (IQR)		53.25 (50.83-55.57)
CH (deviated side) (mm), Median (IQR)		23.62 (21.71-25.63)
CH (non-deviated side) (mm), Median (IQR)		23.33 (21.93-25.99)
CW (deviated side) (mm), Median (IQR)		13.66 (12.55-14.84)
CW (non-deviated side) (mm), Median (IQR)		13.60 (12.56-14.56)
AL (mm), Median (IQR)		53.39 (51.40-56.37)
UPW (mm), Median (IQR)		55.57 (53.27-57.96)

Note: IQR: Interquartile range; PAH: Height of the piriform aperture, PAW: Width of the piriform aperture; UAFH: Upper anterior face height; CH: Choana height; CW: Choana width; AL: Airway length; UPW: Upper palate width.

**Table 2: Comparison of the pre and postoperative NOSE scale scores of the patients**

	Preoperative, mean (95% CI)	Postoperative, mean (95% CI)	Difference, mean (95% CI)	p*
NOSE Score	60.50 (53.71 - 67.30)	7.33 (4.04 - 10.62)	-53.17 (-59.68 - -46.66)	<0.001

\*Related-Samples Wilcoxon Signed Rank Test was used.

both before and after decongestion, there were statistically significant differences between all pre and postoperative acoustic rhinometry parameters of deviated and non-deviated sides of the nose both before and after decongestion.

Table 4 presents the comparison of the pre and postoperative rhinomanometry parameters of the patients. There were statistically significant improvements in all postoperative airflow and airway resistance parameters of the deviated side of the nose before decongestion when compared to preoperative measurements. Also, there was a statistically significant difference between pre and postoperative inspiration airway resistance of the deviated side of the nose after decongestion.

Table 5 shows the statistically significant correlations between anatomical measurements, differences in functional measurements, and differences in NOSE scores of the patients.

There were moderate positive correlations between the CW of the deviated side of the nose, UPW, and difference in NOSE score (R:0.429, p:0.018 and R:0.397, p:0.030). Similarly, there was a large positive correlation between the CW of the non-deviated side of the nose and the difference in NOSE scores (R:0.514, p:0.004). There were statistically significant moderate positive correlations between differences in acoustic rhinometry measurements such as Vol1 of the deviated side of the nose before decongestion, Vol2 of the non-deviated side of the nose before deviation, tVol1 of the non-deviated side of the nose before decongestion, TVol1 before decongestion, and difference in NOSE score.

The difference in flow parameters of the rhinomanometry of the deviated side of the nose which showed moderate negative correlations with difference in NOSE scores were Flowins, Flowex, and tFlow after decongestion. However, the

**Table 3: Comparison of the pre and postoperative acoustic rhinometry parameters of the patients**

Parameter	Side	Decongestion	Preoperative, mean (95% CI)	Postoperative, mean (95% CI)	Difference, mean (95% CI)	p*
MCA1 (cm <sup>2</sup> )	Deviated	Before	0.443 (0.383-0.502)	0.569 (0.522-0.616)	0.127 (0.091-0.162)	<0.001
		After	0.487 (0.434-0.540)	0.605 (0.561-0.650)	0.118 (0.077-0.159)	<0.001
	Non-deviated	Before	0.587 (0.544-0.630)	0.679 (0.643-0.715)	0.092 (0.049-0.135)	<0.001
		After	0.598 (0.558-0.638)	0.684 (0.651-0.717)	0.087 (0.057-0.116)	<0.001
MCA2 (cm <sup>2</sup> )	Deviated	Before	0.495 (0.393-0.598)	0.580 (0.500-0.661)	0.085 (0.014-0.156)	0.006
		After	0.502 (0.432-0.571)	0.636 (0.556-0.716)	0.134 (0.071-0.197)	<0.001
	Non-deviated	Before	0.783 (0.712-0.854)	0.838 (0.751-0.925)	0.055 (-0.023-0.133)	0.198
		After	0.853 (0.760-0.947)	0.940 (0.845-1.036)	0.087 (-0.018-0.192)	0.245
Vol1 (cm <sup>3</sup> )	Deviated	Before	1.810 (1.666-1.953)	1.987 (1.852-2.122)	0.177 (0.058-0.297)	0.001
		After	1.766 (1.651-1.881)	2.007 (1.880-2.135)	0.241 (0.162-0.320)	<0.001
	Non-deviated	Before	1.792 (1.676-1.908)	2.061 (1.948-2.175)	0.269 (0.192-0.346)	<0.001
		After	1.785 (1.659-1.911)	2.070 (1.961-2.179)	0.285 (0.211-0.358)	<0.001
Vol2 (cm <sup>3</sup> )	Deviated	Before	4.513 (3.460-5.566)	6.405 (5.667-7.143)	1.892 (1.102-2.681)	<0.001
		After	5.265 (4.392-6.137)	7.600 (6.796-8.404)	2.335 (1.441-3.230)	<0.001
	Non-deviated	Before	5.570 (4.638-6.502)	6.677 (6.017-7.337)	1.107 (0.204-2.010)	0.002
		After	6.905 (5.915-7.895)	8.014 (7.331-8.697)	1.110 (0.264-1.955)	0.024
tVol (cm <sup>3</sup> )	Deviated	Before	6.323 (5.203-7.442)	8.392 (7.636-9.147)	2.069 (1.266-2.872)	<0.001
		After	7.031 (6.123-7.939)	9.607 (8.781-10.434)	2.577 (1.675-3.478)	<0.001
	Non-deviated	Before	7.362 (6.404-8.320)	8.738 (8.091-9.385)	1.377 (0.458-2.296)	0.001
		After	8.690 (7.683-9.696)	10.084 (9.399-10.769)	1.394 (0.515-2.273)	0.010
TVol (cm <sup>3</sup> )	Before	13.684 (12.085-15.283)	17.130 (15.984-18.276)	3.446 (2.224-4.667)	<0.001	
	After	15.720 (14.204-17.237)	19.691 (18.356-21.027)	3.971 (2.726-5.216)	<0.001	

Note: MCA1: Minimal cross-sectional area 1 of one side of nasal cavity; MCA2: Minimal cross-sectional area 2 of one side of nasal cavity; Vol1: Volume 1 of one side of nasal cavity; Vol2: Volume 2 of one side of nasal cavity; tVol: Total volume of one side of nasal cavity; TVol: Total volume of two sides of nasal cavity.

\*Related-Samples Wilcoxon Signed Rank Test was used.

difference in flow parameters of the rhinomanometry of the non-deviated side of the nose which showed moderate positive correlations with the difference in NOSE scores were Flowex, and tFlow after decongestion. Additionally, the difference in airway resistance parameters of the deviated side of the nose which had moderate positive correlations with the difference in NOSE scores were ARins after decongestion, ARex before decongestion, ARex after decongestion, and tAR before decongestion.

## DISCUSSION

The major expectancy of patients who have a septoplasty operation due to nasal septum deviation is to have more comfortable nasal breathing (5, 17). However, the main postoperative outcome is the satisfaction and improvement of the quality of life of the patient. The effectiveness of the performed surgery is evaluated by the patients and can be accepted as a success if their preoperative symptoms related to nasal septum deviation are completely improved and they feel an apparent increase in life quality (6). Therefore, the patient's feelings and welfare evaluated by the subjective measurements

provide a more meaningful picture of the effectiveness of the applied surgery than the objective methods (17). However, the subjective nature of these methods is a challenge, especially in repeated measures. Follow-up measures are performed by the surgeons to show the ongoing effectiveness of the performed surgery at 3, 6, or 12 months after septoplasty. Therefore, lots of investigators use objective measurements besides the subjective ones, and also investigate their correlations (5, 18).

In the literature, lots of studies have used symptom score questionnaires such as the NOSE score, which is one of the most widely used. These questionnaires provide valuable information about the severity of nasal obstruction from a patient's point of view, and also about the degree of postoperative satisfaction (5, 19). Eren et al. reported a significant decrease in the NOSE score of patients with nasal obstruction after septoplasty (20). Mondina et al. stated that all NOSE scores of patients with nasal obstruction decreased significantly after an applied septoplasty operation (10). Lodder et al. reported that the mean preoperative and postoperative NOSE score was 78.4 and 23.0, respectively, and the mean improvement was 55.4 (21). We found similar results in the literature that the mean

**Table 4: Comparison of the pre and postoperative rhinomanometry parameters of the patients**

Parameter	Side	Decongestion	Preoperative, mean (95% CI)	Postoperative, mean (95% CI)	Difference, mean (95% CI)	p*
Flow <sub>ins</sub> (cm <sup>3</sup> /s)	Deviated	Before	269.70 (238.35-301.06)	344.93 (329.98-359.89)	75.23 (41.60-108.87)	<b>&lt;0.001</b>
		After	318.67 (297.40-339.93)	340.63 (331.53-349.74)	21.97 (-1.49-45.43)	0.052
	Non-deviated	Before	329.43 (321.66-337.20)	348.23 (324.05-372.42)	18.80 (-9.32-46.92)	0.616
		After	364.33 (330.68-397.99)	357.17 (333.42-380.91)	-7.17 (-51.88-37.55)	0.854
Flow <sub>ex</sub> (cm <sup>3</sup> /s)	Deviated	Before	296.87 (267.61-326.12)	363.77 (347.18-380.35)	66.90 (36.10-97.70)	<b>0.003</b>
		After	355.53 (330.27-380.80)	358.20 (346.16-370.24)	2.67 (-24.75-30.08)	0.787
	Non-deviated	Before	347.93 (338.03-357.83)	371.50 (341.70-401.30)	23.57 (-13.07-60.20)	0.673
		After	394.30 (355.00-433.60)	383.93 (353.86-414.01)	-10.37 (-63.16-42.43)	0.880
tFlow (cm <sup>3</sup> /s)	Deviated	Before	566.57 (507.84-625.30)	708.70 (677.52-739.88)	142.13 (79.51-204.76)	<b>0.001</b>
		After	674.20 (629.56-718.84)	698.83 (677.91-719.75)	24.63 (-24.25-73.52)	0.309
	Non-deviated	Before	677.37 (660.36-694.37)	719.73 (665.85-773.62)	42.37 (-22.05-106.79)	0.666
		After	758.63 (686.54-830.73)	741.10 (687.42-794.79)	-17.53 (-114.34-79.27)	0.948
TFlow (cm <sup>3</sup> /s)	Before	1243.93 (1182.18-1305.69)	1428.43 (1350.71-1506.16)	184.50 (89.30-279.70)	<b>0.001</b>	
	After	1432.83 (1343.25-1522.42)	1439.93 (1372.74-1507.12)	7.10 (-103.32-117.52)	0.116	
AR <sub>ins</sub> (150Pa/cm <sup>3</sup> /s)	Deviated	Before	0.685 (0.529-0.840)	0.440 (0.425-0.455)	-0.245 (-0.400 - -0.089)	<b>&lt;0.001</b>
		After	0.496 (0.445-0.546)	0.442 (0.432-0.453)	-0.053 (-0.105 - -0.001)	<b>0.048</b>
	Non-deviated	Before	0.457 (0.447-0.467)	0.442 (0.421-0.462)	-0.016 (-0.042 - -0.011)	0.649
		After	0.432 (0.402-0.462)	0.431 (0.410-0.452)	-0.002 (-0.042-0.039)	0.787
AR <sub>ex</sub> (150Pa/cm <sup>3</sup> /s)	Deviated	Before	0.579 (0.477-0.682)	0.417 (0.403-0.432)	-0.162 (-0.263 - -0.061)	<b>0.002</b>
		After	0.437 (0.408-0.467)	0.422 (0.410-0.433)	-0.016 (-0.047-0.016)	0.658
	Non-deviated	Before	0.434 (0.421-0.448)	0.416 (0.396-0.436)	-0.018 (-0.049-0.013)	0.704
		After	0.402 (0.373-0.431)	0.404 (0.382-0.426)	0.002 (-0.037-0.041)	0.957
tAR (150Pa/cm <sup>3</sup> /s)	Deviated	Before	0.309 (0.249-0.369)	0.214 (0.207-0.221)	-0.095 (-0.155 - -0.036)	<b>0.001</b>
		After	0.231 (0.213-0.249)	0.216 (0.211-0.221)	-0.015 (-0.034-0.003)	0.284
	Non-deviated	Before	0.223 (0.217-0.228)	0.214 (0.204-0.224)	-0.008 (-0.022-0.006)	0.688
		After	0.208 (0.193-0.223)	0.208 (0.198-0.219)	0.000 (-0.019-0.020)	0.905
TAR (150Pa/cm <sup>3</sup> /s)	Before	0.123 (0.116-0.131)	0.107 (0.103-0.111)	-0.017 (-0.025 - -0.009)	<b>0.001</b>	
	After	0.107 (0.102-0.113)	0.106 (0.102-0.109)	-0.002 (-0.008-0.005)	0.116	

Note: Flow<sub>ins</sub>: Inspiration airflow of one side of nasal cavity; Flow<sub>ex</sub>: Expiration airflow of one side of nasal cavity; tFlow: Total airflow of one side of nasal cavity; TFlow: Total airflow of two sides of nasal cavity; AR<sub>ins</sub>: Inspiration airway resistance of one side of nasal cavity; AR<sub>ex</sub>: Expiration airway resistance of one side of nasal cavity; tAR: Total airway resistance of one side of nasal cavity; TAR: Total airway resistance of two sides of nasal cavity.

\*Related-Samples Wilcoxon Signed Rank Test was used.

preoperative and postoperative NOSE score was 60.50 and 7.33, respectively, with a mean difference of 53.17 points. This difference was found to be statistically significant.

In a study, it was reported that an improvement in NOSE score of approximately 40% or higher was required to define the surgery as successful (22). Also, changes in NOSE scores after surgery were evaluated in a systematic review and meta-analysis, and the mean improvement was found as 50.0 points at the early evaluation (12). Stewart et al. demonstrated a 31 to 37 points change in NOSE score in their original septoplasty study (23). In our study, all patients had improvements of more than 30 points in NOSE scores, except two patients with improvement scores of less than 30 points.

AR and AAR measurements have been performed after decongestion of the nose with a topical decongestant in the studies that investigated the effectiveness of the septoplasty (6, 11, 21). The use of nasal decongestants eliminates vascular causes of nasal obstruction and provides a more appropriate evaluation chance for the hard tissue components of nasal obstruction (6). In our study, we measured all parameters BD and AD and took part in AR and AAR measures. We have demonstrated a comparison of preoperative and postoperative results in Tables 3 and 4 and exhibited the statistically significant correlations between the differences in objective measurements and the differences in NOSE scores of the patients. In our study, we found statistically

**Table 5: Statistically significant correlations between anatomical measurements, differences in functional measurements and differences in NOSE scores**

		Difference in NOSE score		
		R	n	p*
Anatomical measurements	CW (DS)	0.429	30	<b>0.018</b>
	CW (NDS)	0.514	30	<b>0.004</b>
	UPW	0.397	30	<b>0.030</b>
Difference in functional measurements	Vol1 (cm <sup>3</sup> ) (DS/BD)	-0.438	30	<b>0.015</b>
	Vol2 (cm <sup>3</sup> ) (NDS/BD)	-0.377	30	<b>0.040</b>
	tVol1 (cm <sup>3</sup> ) (NDS/BD)	-0.401	30	<b>0.028</b>
	TVol1 (cm <sup>3</sup> ) (BD)	-0.372	30	<b>0.043</b>
	Flow <sub>ins</sub> (cm <sup>3</sup> /s) (DS/AD)	-0.409	30	<b>0.025</b>
	Flow <sub>ex</sub> (cm <sup>3</sup> /s) (DS/AD)	-0.396	30	<b>0.030</b>
	Flow <sub>ex</sub> (cm <sup>3</sup> /s) (NDS/AD)	0.367	30	<b>0.046</b>
	tFlow (cm <sup>3</sup> /s) (DS/AD)	-0.396	30	<b>0.030</b>
	tFlow (cm <sup>3</sup> /s) (NDS/AD)	0.365	30	<b>0.047</b>
	AR <sub>ins</sub> (150Pa/cm <sup>3</sup> /s) (DS/AD)	0.418	30	<b>0.022</b>
	AR <sub>ex</sub> (150Pa/cm <sup>3</sup> /s) (DS/BD)	0.366	30	<b>0.047</b>
	AR <sub>ex</sub> (150Pa/cm <sup>3</sup> /s) (DS/AD)	0.412	30	<b>0.024</b>
	AR <sub>ex</sub> (150Pa/cm <sup>3</sup> /s) (NDS/AD)	-0.368	30	<b>0.045</b>
	tAR (150Pa/cm <sup>3</sup> /s) (DS/BD)	0.405	30	<b>0.026</b>

Note: CW: Choana width; UPW: Upper palate width; Vol1: Volume 1 of one side of nasal cavity; Vol2: Volume 2 of one side of nasal cavity; tVol: Total volume of one side of nasal cavity; TVol: Total volume of two sides of nasal cavity; Flow<sub>ins</sub>: Inspiration airflow of one side of nasal cavity; Flow<sub>ex</sub>: Expiration airflow of one side of nasal cavity; tFlow: Total airflow of one side of nasal cavity; AR<sub>ins</sub>: Inspiration airway resistance of one side of nasal cavity; AR<sub>ex</sub>: Expiration airway resistance of one side of nasal cavity; tAR: Total airway resistance of one side of nasal cavity; DS: Deviated side; NDS: Non-deviated side; BD: Before decongestion; AD: After decongestion.

\* Spearman's rank-order correlation was used.

significant differences between all pre and postoperative acoustic rhinometry variables (Except for the MCA2 of NDS) of DS and NDS of the nose both before and after decongestion. We also found significant improvements in all postoperative airflow and airway resistance parameters of DS of the nose before decongestion, when compared to the preoperative measurements.

Although AR provides detailed information about the geometry of nasal structures, it does not provide any information about the flow field and physiology of nasal pressure (5, 17). These parameters have critical importance because the evaluation of the physiology of the nasal airway helps surgeons to decide which patients would get better from performing a septoplasty operation (17). AAR provides detailed information about the physiology of nasal airflow and demonstrates abnormal measurements in nasal airflow and nasal pressure. Also, studies have reported that patients with severe anatomic deviation may have mild symptoms, whereas other patients with a small septal deviation have significant nasal obstruction symptoms (1). It is thought that these characteristics of AAR complete the missing parts of other objective measurements such as morphometric variables and AR measures (24).

Lara-Sanches et al. reported that performed surgery resulted in statistically significant differences with the NOSE score and

AAR measures. They did not, however, observe any correlation between the NOSE score and AAR, and concluded that the objective and subjective measurements complete each other and provide useful information from a different point of view (25). Currently, the correlation between the subjective evaluation scores and detailed objective measurements is still debated. Several studies showed correlation, whereas others did not (2, 5, 17, 26). It was pointed out that the correlation between NOSE score and objective evaluations could be affected by study design, such as having a small sample size, non-homogenous groups, or the surgical techniques performed (12, 27). Jones et al. observed no correlation between the objective nasal resistance measurements and subjective measures (28).

It has been stated in the literature that the lack of correlation between the objective and subjective measurements related to nasal function may be due to surgeons focusing on the nasal passage of the deviated side and ignoring the fact that the nose has two separate nasal passages (5). In a study, a significant nasal airflow increase was observed on the deviated side, but a significant airflow decrease was not observed on the non-deviated (wide side) part (29). In another study, during follow-up measurements, a significant increase in nasal resistance was observed in the non-deviated nasal cavity in 23 of 30

patients with nasal obstruction (30). In the presented study, surgery significantly increased nasal airflow and reduced nasal resistance in the deviated side of the nasal septum, but did not cause any significant airflow or nasal resistance changes in the non-deviated side. It has been thought in the literature that asymmetrical nasal airflow resulting from deviated nasal septum may create spontaneous changes in the nasal cycle and that may lead to the symptoms related to nasal congestions (5).

NOSE score refers to subjective feelings about the nasal patency, AR and AAR provide additional objective detailed information on the anatomy of the nasal cavity, nasal airflow, and nasal resistance, respectively (5). In our study, we performed both objective measurements in all patients and investigated the existence of a correlation between NOSE score, AR, and AAR measurements. We then demonstrated significant correlations between the NOSE score and lots of AR and AAR parameters.

There are several limitations in the presented study. First, we could have studied a relatively smaller group of patients. Also, we did not include a control group. Another limitation of our study was the short follow-up time because several studies have reported that the improvement in symptoms and subjective evaluations at early stages decreased at the long term observation (31). In the presented study, the control measures of patients were performed at the end of the first month and therefore, we cannot comment on the long-term consequences of the surgery.

## CONCLUSION

Many different follow-up and evaluation methods have been proposed to evaluate the effectiveness of the performed operations in septoplasty surgery. Some of them include subjective measurements and others include objective measurements. We performed both methods in the presented study, and then investigated the correlation of these tests. We showed that objective measurements correlate strongly with the subjective one, and further studies should be conducted to evaluate positive or negative preoperative predictors of surgical outcomes.

**Ethics Committee Approval:** Ethical approval was obtained from Izmir Tepecik Training and Research Hospital Ethics Committee (Approval date:18/08/2016, No:22)

**Informed Consent:** Written informed consent was obtained from all patients included in the study after detailed information about the study was given.

**Peer-Review:** Externally peer-reviewed.

**Author Contributions:** Conception/Design of Study- A.U., E.D.; Data Acquisition- A.U., E.D.; Data Analysis/Interpretation- A.U., E.D.; Drafting Manuscript- A.U., E.D.; Critical Revision of Manuscript- A.U., E.D.; Final Approval and Accountability- A.U., E.D.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support

## REFERENCES

1. Konstantinidis I, Triaridis S, Triaridis A, Karagiannidis K, Kontzoglou G. Long term results following nasal septal surgery. Focus on patients' satisfaction. *Auris, Nasus, Larynx* 2005;32(4):369-74.
2. Tsang CLN, Nguyen T, Sivesind T, Cervin A. Long-term patient-related outcome measures of septoplasty: a systematic review. *European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery* 2018;275(5):1039-48.
3. Sedaghat AR, Busaba NY, Cunningham MJ, Kieff DA. Clinical assessment is an accurate predictor of which patients will need septoplasty. *Laryngoscope* 2013;123(1):48-52.
4. Shah J, Roxbury CR, Sindwani R. Techniques in Septoplasty: Traditional Versus Endoscopic Approaches. *Otolaryngol Clin North Am* 2018;51(5):909-17.
5. Hsu HC, Tan CD, Chang CW, Chu CW, Chiu YC, Pan CJ, et al. Evaluation of nasal patency by visual analogue scale/nasal obstruction symptom evaluation questionnaires and anterior active rhinomanometry after septoplasty: a retrospective one-year follow-up cohort study. *Clin Otolaryngol* 2017;42(1):53-9.
6. Moore M, Eccles R. Objective evidence for the efficacy of surgical management of the deviated septum as a treatment for chronic nasal obstruction: a systematic review. *Clin Otolaryngol* 2011;36(2):106-13.
7. Fettman N, Sanford T, Sindwani R. Surgical management of the deviated septum: techniques in septoplasty. *Otolaryngol Clin North Am* 2009;42(2):241-52.
8. Kim JS, Heo SJ. Questionable Effect of Crosshatching Incision in Septoplasty. *Clin Exp Otorhinolaryngol* 2020;13(1):47-51.
9. Most SP, Rudy SF. Septoplasty: Basic and Advanced Techniques. *Facial Plast Surg Clin North Am* 2017;25(2):161-9.
10. Mondina M, Marro M, Maurice S, Stoll D, de Gabory L. Assessment of nasal septoplasty using NOSE and RhinoQoL questionnaires. *Eur Arch Otorhinolaryngol* 2012;269(10):2189-95.
11. Sahin C. Evaluation of Patient Satisfaction After Nasal Septoplasty Operation Using Peak Nasal Inspiratory Flow and Nasal Obstruction Symptom Score Questionnaire. *J Craniofac Surg* 2016;27(5):1289-91.
12. Floyd EM, Ho S, Patel P, Rosenfeld RM, Gordin E. Systematic Review and Meta-analysis of Studies Evaluating Functional Rhinoplasty Outcomes with the NOSE Score. *Otolaryngol Head Neck Surg* 2017;156(5):809-15.
13. Mladina R. The role of maxillary morphology in the development of pathological septal deformities. *Rhinology*. 1987;25(3):199-205.
14. Aksu F, GMN, Kahveci O, Cirpan S, Karabekir S. Diameters of piriform aperture and choana: An anatomic study. *Dokuz Eylül Univ Sch Med J*. 2013;27(1):1-6.
15. Hilberg O, Pedersen OF. Acoustic rhinometry: recommendations for technical specifications and standard operating procedures. *Rhinol Suppl* 2000;16:3-17.
16. Clement PA, Gordts F. Consensus report on acoustic rhinometry and rhinomanometry. *Rhinology* 2005;43(3):169-79.
17. Cantone E, Ricciardiello F, Oliva F, De Corso E, Iengo M. Septoplasty: is it possible to identify potential "predictors" of surgical success? *Acta Otorhinolaryngol Ital* 2018;38(6):528-35.

18. André RF, Vuyk HD, Ahmed A, Graamans K, Nolst Trenité GJ. Correlation between subjective and objective evaluation of the nasal airway. A systematic review of the highest level of evidence. *Clin Otolaryngol* 2009;34(6):518-25.
19. Apaydin E, İkinçioğulları A, Çolak M, Atan D, Ensari S, Dere HH. The Voice Performance After Septoplasty With Surgical Efficacy Demonstrated Through Acoustic Rhinometry and Rhinomanometry. *J Voice* 2020;34(4):649.e15-.e20.
20. Eren SB, Tugrul S, Dogan R, Ozucer B, Ozturan O. Objective and subjective evaluation of operation success in patients with nasal septal deviation based on septum type. *Am J Rhinol Allergy* 2014;28(4):e158-62.
21. Lodder WL, Leong SC. What are the clinically important outcome measures in the surgical management of nasal obstruction? *Clin Otolaryngol* 2018;43(2):567-71.
22. Ziai H, Bonaparte JP. Determining a Successful Nasal Airway Surgery: Calculation of the Patient-Centered Minimum Important Difference. *Otolaryngol Head Neck Surg* 2017;157(2):325-30.
23. Stewart MG, Smith TL, Weaver EM, Witsell DL, Yueh B, Hannley MT, et al. Outcomes after nasal septoplasty: results from the Nasal Obstruction Septoplasty Effectiveness (NOSE) study. *Otolaryngol Head Neck Surg* 2004;130(3):283-90.
24. Vogt K, Jalowayski AA, Althaus W, Cao C, Han D, Hasse W, et al. 4-Phase-Rhinomanometry (4PR)--basics and practice 2010. *Rhinol Suppl* 2010;21:1-50.
25. Lara-Sánchez H, Álvarez Nuño C, Gil-Carcedo Sañudo E, Mayo Iscar A, Vallejo Valdezate L. Assessment of nasal obstruction with rhinomanometry and subjective scales and outcomes of surgical and medical treatment. *Acta Otorrinolaringol Esp* 2017;68(3):145-50.
26. Mengi E, Cukurova I, Yalçın Y, Yiğitbaşı OG, Karaman Y. [Evaluation of operation success in patients with nasal septal deviation with quality of life scale and objective methods]. *Tr-ENT* 2011;21(4):184-91.
27. Gamerra M, Cantone E, Sorrentino G, De Luca R, Russo MB, De Corso E, et al. Mathematical model for preoperative identification of obstructed nasal subsites. *Acta Otorhinolaryngol Ital.* 2017;37(5):410-5.
28. Jones AS, Willatt DJ, Durham LM. Nasal airflow: resistance and sensation. *J Laryngol Otol* 1989;103(10):909-11.
29. Piriilä T, Tikanto J. Acoustic rhinometry and rhinomanometry in the preoperative screening of septal surgery patients. *Am J Rhinol Allergy* 2009;23(6):605-9.
30. Haavisto LE, Sipilä JI. Acoustic rhinometry, rhinomanometry and visual analogue scale before and after septal surgery: a prospective 10-year follow-up. *Clin Otolaryngol* 2013;38(1):23-9.
31. De Corso E, Bastanza G, Di Donfrancesco V, Guidi ML, Morelli Sbarra G, Passali GC, et al. Radiofrequency volumetric inferior turbinate reduction: long-term clinical results. *Acta Otorhinolaryngol Ital* 2016;36(3):199-205.



# Audiovestibular Manifestations in Autoimmune Disorders: A Case Clinical Control Study in Celiac Patients

Nesrettin Fatih Turgut<sup>1</sup> , Dilek Gülmez<sup>2</sup> , Hasan Ahmet Özdoğan<sup>3</sup> 

<sup>1</sup>University of Health Sciences- Samsun Health Practices and Research Center, Department of Otorhinolaryngology, Samsun, Turkey

<sup>2</sup>Cerrahpasa University, Department of Audiology, Istanbul, Turkey

<sup>3</sup>Cerrahpasa University, Department of Otorhinolaryngology, Istanbul, Turkey

ORCID ID: N.F.T. 0000-0001-6265-0058; D.G. 0000-0001-6265-0058; H.A.Ö. 0000-0003-3049-3208

**Citation:** Turgut NF, Gulmez D, Ozdogan HA. Audiovestibular manifestations in autoimmune disorders: a case clinical control study in celiac patients. Tr-ENT 2021;31(2):34-8. <https://doi.org/10.26650/Tr-ENT.2021.951349>

## ABSTRACT

**Objective:** The aim of this study was to evaluate audiovestibulopathy in patients with celiac disease using vestibular evoked myogenic potentials (VEMP), video head impulse test (vHIT), and audiometric examinations.

**Material and Methods:** Thirty-one patients with celiac disease from the gastroenterology department of Cerrahpasa Medical School, and 30 healthy controls were included in the study between 2013 and 2015. Pure tone audiometry, tympanometry, acoustic reflex test, and vestibular evaluation with VEMP and vHIT were performed in both groups. The anti-tissue transglutaminase IgA levels of all participants and disease duration of affected individuals were documented.

**Results:** The mean age±SD was 35.9±12.82 (27-48) years and 37.6±11.6 (26-48) years for the patient and control groups, respectively. The pure tone thresholds did not differ between the two groups. However, a subgroup of patients with high antibody levels had significantly higher high-frequency hearing thresholds. The two groups had similar VEMP test results, but a comparison of the vestibuloocular reflex (VOR) gains of six semicircular canals (SSC) revealed significant decreases in the right anterior canal in the patient group.

**Conclusion:** Subclinical audiovestibular pathologies can occur in patients with celiac disease. Following these patients with periodic audiovestibular test batteries may reduce patient morbidity by providing early diagnosis and rehabilitation.

**Keywords:** Celiac disease, VEMP, vHIT, vestibuloocular reflex

## INTRODUCTION

Autoimmune diseases are known to play a role in the etiology of sensorineural hearing loss (SNHL) and vestibular dysfunction. This relationship was first reported as a separate clinical condition in 1979 by McCabe, who showed improvement in patients with bilateral progressive hearing loss using corticosteroid treatment (1). Subsequently, it was proposed that autoimmunity was the cause of inner ear pathologies, such as sudden sensorineural hearing loss or acute vertigo, because various autoimmune diseases (e.g., rheumatoid arthritis, polyarthritis nodosa, systemic lupus erythematosus, and ulcerative colitis) may include auditory and vestibular system symptoms (2, 3).

One of the most common autoimmune diseases is celiac disease, a food-related condition of the small intestine in humans (4). The clinical findings of celiac disease are most prominently associated with the intestinal system. However, autoimmune-related neurological system findings are also observed in 6–10% of patients. These neurological findings have been associated with autoimmunity due to the appearance of inflammatory cells in the cerebrospinal fluid, the presence of antibodies in the circulation, and the regression of symptoms after an appropriate diet (5). It has been proposed that the SNHL associated with neurological symptoms develops in patients with celiac disease due to immunological markers such as organ-unspecific autoantibodies and antineural antibodies (6). Therefore, SNHL should be defined as extraintestinal involvement in patients with celiac disease (7).

**Corresponding Author:** Nesrettin Fatih Turgut E-mail: drnftkbb@gmail.com

**Submitted:** 12.06.2021 • **Revision Requested:** 27.06.2021 • **Last Revision Received:** 01.07.2021 • **Accepted:** 14.07.2021



This work is licensed under Creative Commons Attribution-NonCommercial 4.0 International License.

The peripheral vestibular system is also a part of the inner ear and the neurological system. Therefore, we believe that this system could inevitably be affected by autoimmune mediators and that this issue should be tested. The aim of the present study was therefore to evaluate the vestibular system in patients with celiac disease, as well as their audiological systems. To the best of our knowledge, this is the first study to assess the vestibular system using VEMP and vHIT in patients with celiac disease.

## MATERIALS AND METHODS

### Patients and study design

The study was approved by the Istanbul University Cerrahpaşa Medical Faculty Ethics Committee (approval ID: 02/16-47473) and included 31 patients with celiac disease who were diagnosed, followed up, and treated at Cerrahpaşa Medical School Adult Gastroenterology outpatient clinic. A control group of 30 age- and sex-matched healthy volunteers was also included. None of the patients with celiac disease or the healthy volunteers had any audiovestibular complaints. Exclusion criteria included ototoxic drug use, ear surgery history, middle ear pathology, presence of spontaneous nystagmus, or presence of another autoimmune, metabolic, or neurological disease.

### Evaluation of serum antibody levels

The disease activity in patients with celiac disease included in the study was determined by measuring serum anti-tissue transglutaminase IgA levels two weeks prior to the audiovestibular tests. The median value of 12U/mL was used to divide the patients into a low-antibody level group (Group I) and a high-antibody level group (Group II).

### Audiological evaluation

Autoscopic and routine otolaryngological examinations were performed by an expert otolaryngologist on all individuals included in the study. Acoustic impedancemetry and reflex measurements were performed using Interacoustics AZ26 and AT235H (Interacoustics A/S, Denmark) clinical tympanometry devices. Audiological evaluations were made in double-walled IAC (Industrial Acoustic Company, Inc.) soundproof rooms in a standard quiet cabin. An Interacoustics AC 40 clinical audiometer was used to detect air conduction hearing thresholds with TDH 39P Telephonics headphones, and bone conduction hearing thresholds with a Radioear B-71 bone vibrator.

### Vestibular evaluation

The VEMP test was performed with Chartr model EP 200 device (Otometrics, Natus M., Denmark). VEMP recordings were obtained by providing a 95 dB tone-burst stimulus at 500 Hz frequency with an insert headphone. The patients were asked to contract the sternocleidomastoid muscle by turning their head to the opposite side of the stimulated ear. Amplitude and latency values were recorded by detecting p1 and n1 waves.

The vHIT measurements were performed with an ICS impulse system (GN Otometrics, Denmark) vHIT device. During the test, eye movements were recorded with the aid of a pair of slanted glasses held to the head with rubber bands. Depending on the semicircular canal being tested, the test was performed by tilting the head right, left, front, or back by about 15 degrees and waiting for at least one second between consecutive head movements. Individuals with a semicircular canal gain score under 0.7 were considered pathological, while those scoring above 0.7 were considered normal.

### Statistical analyses

SPSS 15.0 for Windows software was used for statistical analyses. Descriptive statistics were given as numbers and percentages for categorical variables and as mean and standard deviation for numerical variables. Comparison of two independent groups was made using the Student's t-test when numerical variables showed normal distribution and with the Mann-Whitney U-test when the variables did not show normal distribution. Ratios in independent groups were tested using Chi-square analysis. Correlations between numerical variables were analyzed using Pearson correlation analysis when a parametric test condition was met and with Spearman correlation analysis when the parametric test condition was not met. Statistical alpha significance level was accepted as  $p < 0.05$ .

## RESULTS

In the celiac patient group included in the study, 11 (35.5%) were male and 20 (64.5%) were female, with a mean age  $\pm$  of  $35.9 \pm 12.82$  years (27–48 years). The mean disease duration was  $10.4 \pm 8.1$  years (1–29 years). Of the healthy volunteers, 14 were female (47%) and 16 were male (53%), with a mean age of  $37.6 \pm 11.6$  years (26–48 years).

The mean anti-tissue transglutaminase IgA level was  $117.1 \pm 132.6$  U/mL (0.7–300) in the patient group. Anti-tissue transglutaminase IgA was below 12 U/mL (Group I) in 15 (48.4%) patients and above this value (Group II) in 16 (51.6%) patients.

### Audiological findings

No statistically significant differences were found between the patient and control group for any of the air and bone conduction frequency measurements. Air conduction thresholds in right and left ears were significantly lower, at 1000, 2000, 4000, and 6000 Hz, and bone conduction thresholds in the right ear were also significantly lower in Group I than in Group II only at 4000 Hz (Table 1). Air conduction thresholds in both ears were significantly higher at all frequencies tested in the group with a disease duration of 10 or more years (Table 2).

Comparison of the gains of vHIT semicircular canals revealed a significantly higher rate of low RA (Right Anterior) in the patient group than in the control group (Table 3).

The results for semicircular canal gain in the vHIT test showed no significant difference between the anti-tissue transglutaminase IgA groups or different disease duration groups.

**Table 1: Comparison of the hearing thresholds (dBHL) in the right and left ear in anti-tissue transglutaminase IgA groups of patients with celiac disease.**

	Right ear			Left ear		
	Group I	Group II	p	Group I	Group II	p
	Mean±SD	Mean±SD		Mean±SD	Mean±SD	
<b>Air Conduction Thresholds</b>						
125 Hz	7.33±5.80	11.56±10.28	0.123	7.67±6.09	10.31±7.18	0.180
250 Hz	7.56±5.80	10.94±8.98	0.173	7.67±5.50	8.13±6.80	0.813
500 Hz	7.00±5.78	10.00±6.06	0.093	7.33±5.39	9.06±4.55	0.255
1000 Hz	7.33±5.60	11.88±6.02	0.011	7.11±5.28	10.00±4.08	0.032
2000 Hz	7.11±5.38	13.75±8.27	0.003	7.33±5.18	13.13±6.80	0.003
4000 Hz	7.11±5.79	17.50±12.91	0.001	7.44±6.27	17.50±15.28	0.001
6000 Hz	8.11±7.48	18.13±10.31	<0.001	8.44±7.22	17.50±12.52	0.002
<b>Bone Conduction Thresholds</b>						
500Hz	5.78±4.76	6.25±7.19	0.871	5.67±4.34	5.00±5.16	0.575
1000Hz	6.36±5.10	6.25±7.42	0.530	5.67±4.21	4.69±4.27	0.466
2000Hz	6.22±5.66	8.44±9.61	0.778	5.89±4.56	7.19±8.16	0.904
4000Hz	6.22±6.23	13.75±13.23	0.031	6.56±5.82	13.13±14.13	0.091

A comparison of VEMP quantitative values in patient and control groups is summarized in Table 4. No significant differences were noted between the right and left ear p1 and n1 latencies and amplitudes in the anti-tissue transglutaminase IgA groups or in the different disease duration groups.

The differences in the right and left ear p1 and n1 latency and amplitudes between patient and control groups were not statistically significant.

## DISCUSSION

The pathophysiology of systemic autoimmune diseases has not yet been fully unraveled, but some publications suggest that these diseases can affect the audiovestibular system through cross-reaction, immune complex accumulation, vasculitis, or the passage of autoantibodies to the perilymph through the cerebrospinal fluid (8). The involvement of the audiovestibular system in celiac disease, an autoimmune disease, is apparently inevitable. In patients with celiac disease, the effects of the disease on the audiological system have been investigated. However, not enough attention has been paid to any potential effects on the vestibular system. To the best of our knowledge of the literature available to us, we believe that our study, with its aim of understanding the effect of celiac disease on the vestibular and audiological systems, is the first to investigate this relationship using VEMP and vHIT test batteries in this group of patients.

Autoimmune inner ear disease is clinically heterogeneous and depends on the type of immune reaction and the location of the damage to the inner ear. One study conducted in patients with psoriatic arthritis, another immune-mediated inflammatory disease, showed increases in the frequency of audiovestibular symptoms, such as hearing impairment and

vertigo, and detected bilateral sensorineural hearing loss in these patients, especially at high frequencies. In addition, hearing loss prevalence was significantly higher in patients with psoriatic arthritis compared to the control group (9). Leggio et al. reported that 41.7% of patients with celiac disease had SNHL and suggested that SNHL might be considered an extraintestinal symptom of celiac disease and that immunological markers might be effective for monitoring the formation of SNHL in these patients. (10) Similarly, Umberto et al. found a higher prevalence of SNHL in patients with celiac disease than in healthy controls; however, the difference was not statistically significant (11). They also found no correlation between SNHL findings in patients with celiac disease and the presence of immunological markers (11).

In another study on pediatric patients with celiac disease, Urganci et al. found no statistically significant differences in patients in terms of mean hearing levels, disease activity and duration, or other extraintestinal symptoms (12). Conversely, Karabulut et al. performed hearing evaluations including tests of the medial olivocochlear efferent system in pediatric patients with celiac disease and found a statistically significant difference in the pure tone thresholds at 250 Hz frequency between the patient and control groups (13). In our study, no significant difference was found in the pure tone thresholds in both ears between the patient and control groups; however, comparison of the anti-tissue transglutaminase IgA groups revealed significantly higher pure tone thresholds at the 1000Hz, 2000Hz, 4000Hz, and 6000Hz frequencies in the high antibody group than in the low antibody group. This observation of hearing impairment at high frequencies in a high antibody group might be explained by the fact that more arterial structures are present in the cochlea base than in the apex; thus, the effect of autoantibodies could be more prominent in this region.

**Table 2: Comparison of hearing thresholds (dBHL) in the right and left ears with celiac disease duration.**

	Right ear		p	Left ear		p
	Disease duration			Disease duration		
	Less than 10 years	10 years or more		Less than 10 years	10 years or more	
	Mean±SD	Mean±SD		Mean±SD	Mean±SD	
<b>Air Conduction Thresholds</b>						
125 Hz	6.18±5.16	13.21±10.49	0.026	6.47±4.60	12.50±8.03	0.023
250 Hz	5.29±4.83	13.93±8.13	0.002	5.59±4.64	11.07±5.94	0.009
500 Hz	4.71±4.50	12.50±5.80	0.000	5.88±4.41	11.07±4.01	0.002
1000 Hz	6.47±4.24	13.57±6.33	0.002	6.18±4.52	11.07±3.50	0.003
2000 Hz	7.06±4.70	14.29±8.96	0.017	7.65±4.72	13.57±6.91	0.012
4000 Hz	7.65±7.52	17.50±13.27	0.011	7.06±7.51	17.86±15.28	0.002
6000 Hz	7.35±6.64	19.64±10.46	0.001	7.06±5.88	20.36±11.51	<0.001
<b>Bone Conduction Thresholds</b>						
500Hz	2.94±3.56	8.21±7.75	0.046	3.82±4.52	5.36±4.58	0.311
1000Hz	2.19±3.15	9.29±6.75	0.001	2.65±3.59	6.43±3.06	0.005
2000Hz	2.94±3.56	10.36±10.09	0.039	4.12±3.64	7.86±8.48	0.293
4000Hz	4.41±6.82	13.93±13.61	0.014	5.59±6.09	12.86±14.77	0.119

**Table 3: Comparison of vHIT semicircular canal gain in patients with celiac disease and healthy controls.**

		Patient group		Control group		p
		n	%	n	%	
RA	Normal	20	64.5	27	90.0	0.018
	Low	11	35.5	3	10.0	
LA	Normal	26	83.9	30	100	0.053
	Low	5	16.1	0	0.0	
RP	Normal	31	100.0	27	90.0	0.113
	Low	0	0.0	3	10.0	
LP	Normal	30	96.8	28	96.6	1.000
	Low	1	3.2	1	3.4	
RL	Normal	29	96.7	28	93.3	1.000
	Low	1	3.3	2	6.7	
LL	Normal	29	100	30	100	-

RA: right anterior; LA: left anterior; RP: right posterior; LP: left posterior; RL: right lateral; LL: left lateral

An important point to note is that autoimmune diseases cause inner ear involvement through autoimmune mediators, and this situation will affect the vestibular system in addition to the hearing system. In their immune-mediated inner ear disease review, Bovo et al. concluded that the vestibular system was affected in 50% of autoimmune inner ear patients, and that these vestibular system symptoms include imbalance, ataxia, positional vertigo, and episodic vertigo (8).

**Table 4: Comparison of VEMP quantitative values in patients with celiac disease and healthy controls.**

	Patient group		Control group	p
	Mean±SD	Mean±SD		
Right p1 latency	14.16±2.01	14.82±2.67		0.658
Right n1 latency	20.80±3.43	21.03±1.86		0.744
Right p1 amplitude	32.82±3.30	34.66±4.94		0.093
Right n1 amplitude	43.29±3.70	44.68±5.72		0.064
Left p1 latency	14.03±2.67	14.59±2.48		0.649
Left n1 latency	21.00±3.81	20.61±2.48		0.640
Left p1 amplitude	34.44±3.37	35.62±5.17		0.650
Left n1 amplitude	43.46±3.30	44.90±5.76		0.051

In a case study presenting Behçet's disease manifesting with peripheral vestibulopathy, Alison et al. reported that a 66-year-old male patient being followed up with hearing and vestibular system complaints was diagnosed with Behçet's disease as mouth and genital ulcers developed approximately ten years after the initial complaints (14). An evaluation of the vestibular system of this patient using ice-water caloric stimulation revealed permanent right canal paralysis and low amplitude response in both ears. His vHIT test revealed catch-up saccades in right side rotation, fewer saccades in left side rotation, and a significant decrease in VOR gain, while his VEMP test showed a lack of right ear stimulation, suggesting weakness in the right otolith organs. In that case study, the authors emphasized that

patients who were referred to a clinic with peripheral vestibular system pathologies and SNHL should be evaluated in detail and investigated for the presence of an underlying autoimmune disease (14).

Nahid et al. used VEMP to evaluate the vestibular system in patients with rheumatoid arthritis, another commonly observed autoimmune disease (15). The cVEMP measurements of 25 rheumatoid arthritis patients and 20 healthy controls with a stimulus intensity of 95 dBnHL at 500 Hz turn-burst stimulation revealed no significant difference in absolute or interaural amplitudes between the two groups. However, prolonged latency was detected in the patient group. Prolonged latency is an abnormal characteristic finding of central vestibulopathy and has been reported to indicate vestibulospinal path lesions; therefore, the authors suggested that vestibular rehabilitation may be useful in early diagnosis.

Pawlak-Oniskia et al. evaluated the vestibular system in a pediatric celiac patient group using ENG and VEMP test batteries but found no significant difference in VEMP results between the patients and healthy controls (16). However, the ENG results frequently indicated gaze nystagmus, disordered eye-tracking, and optokinetic nystagmus, and the authors argued that these findings support the hypothesis that neurological findings may be observed early in patients with celiac disease. In our study, we evaluated the vestibular system in patients with celiac disease using vHIT and VEMP test batteries. The VEMP test results did not differ significantly between the patient and control groups. However, the vHIT results revealed a greater frequency of low right anterior semicircular canal gain in the celiac patient group. This observation could be a finding of subclinical vestibular pathology; therefore, we believe it is important that these patients be followed up for vestibular pathologies as well.

The small sample size in the present study and the use of vHIT and VEMP test batteries alone for vestibular evaluation are the most significant limitations of this study. Therefore, we suggest that a need exists for the evaluation of the vestibular systems of large groups of patients with celiac disease using additional test batteries.

## CONCLUSION

The effects of systemic autoimmune diseases on the audiovestibular system necessitate the screening of patients with appropriate test batteries for early diagnosis, as this will enable early detection of potential inner ear damage. Audiovestibular rehabilitation can then prevent the increase in morbidity in these patients. Our data showed that subclinical audiovestibular pathologies may occur in patients with celiac disease, another autoimmune disease. We believe that periodic follow-up of these patients with audiovestibular test batteries may reduce patient morbidity by providing patients with early diagnosis and timely implementation of rehabilitation programs.

**Ethics Committee Approval:** The study was approved by the Istanbul University Cerrahpaşa Medical Faculty Ethics Committee (approval ID: 02/16-47473).

**Informed Consent:** Written informed consent was obtained from all patients included in the study after detailed information about the study was given.

**Peer-Review:** Externally peer-reviewed.

**Author Contributions:** Conception/Design of Study- N.F.T., D.G.; Data Acquisition- N.F.T., D.G.; Data Analysis/Interpretation- N.F.T.; Drafting Manuscript- N.F.T., D.G.; Critical Revision of Manuscript- A.H.Ö.; Final Approval and Accountability- N.F.T., A.H.Ö.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

## REFERENCES

1. McCabe BF. Autoimmune sensorineural hearing loss. *Ann Otol Rhinol Laryngol* 1979;88:585-9.
2. Harris J, Ryan A. Fundamental immune mechanisms of the brain and inner ear. *Otolaryngol - Head Neck Surg* 1995;112:639-53.
3. Öztürk A, Yalçın Ş, Kaygusuz I, Şahin S, Gök Ü, Karlıdağ T, Ardiçoğlu Ö. High-frequency hearing loss and middle ear involvement in rheumatoid arthritis. *Am J Otolaryngol* 2004;25:411-7.
4. Farrell RJ, Kelly CP. Diagnosis of celiac sprue. *Am J Gastroenterol* 2001;96:3237-46.
5. Briani C, Zara G, Alaedini A, Grassivaro F, Ruggero S, Toffanin E, et al. Neurological complications of celiac disease and autoimmune mechanisms: a prospective study. *J Neuroimmunol* 2008;195:171-5.
6. Alaedini A, Green PH. Narrative review: celiac disease: understanding a complex autoimmune disorder. *Ann Intern Med* 2005;142:289-98.
7. Green PH, Jabri B. Celiac disease. *Annu Rev Med* 2006;57:207-21.
8. Bovo R, Aimoni C, Martini A. Immune-mediated inner ear disease. *Acta Otolaryngol* 2006;126:1012-21.
9. Amor-Dorado JC, Barreira-Fernandez MP, Pina T, Vázquez-Rodríguez TR, Llorca J, González-Gay MA. Investigations into audiovestibular manifestations in patients with psoriatic arthritis. *J Rheumatol* 2014;41:2018-26.
10. Leggio L, Cadoni G, D'Angelo C, Mirijello A, Scipione S, Ferrulli A, et al. Coeliac disease and hearing loss: preliminary data on a new possible association. *Scand J Gastroenterol* 2007;42:1209-13.
11. Volta U, Ferri GG, De Giorgio R, Fabbri A, Parisi C, Sciajno L, et al. Sensorineural hearing loss and celiac disease: a coincidental finding. *Can J Gastroenterol* 2009;23:531-5.
12. Urganci N, Kalyoncu D, Calis AB. Sensorineural hearing loss in pediatric patients with celiac disease. *Eur Arch Otorhinolaryngol* 2015;272:2149-51.
13. Karabulut H, Hizli S, Dagli M, Karabulut I, Acar B, Celik E, et al. Audiological findings in celiac disease. *ORL J Otorhinolaryngol Relat Spec* 2011;73:82-7.
14. White AS, Taylor RL, McNeill C, Garsia R, Welgampola MS. Behçet's disease presenting as a peripheral vestibulopathy. *J Clin Neurosci* 2014;21:1060-3.
15. Heydari N, Hajiabolhassan F, Fatahi J, Movaseghi S, Jalaie S. Vestibular function can be affected by autoimmune processes in rheumatoid arthritis. *Aud Vest Res* 2015;24:193-200.
16. Pawlak-Osińska K, Kaźmierczak H, Kuczyńska R, Szaflarska-Popławska. Looking for the auditory and vestibular pathology in celiac disease [in Polish]. *Otolaryngol Pol* 2007;61:178-83.

# Do Tumor Board Recommendations Influence the Decisions of Clinicians in Planning the Treatment of Head and Neck Cancers?

Gökhan Akgül<sup>1</sup> , Nesrettin Fatih Turgut<sup>1</sup> , Mehmet Dursun Mehel<sup>1</sup> , Serap Aydoğdu<sup>2</sup> ,  
Abdulkadir Özgür<sup>3</sup> 

<sup>1</sup>University of Health Sciences Turkey, Samsun Health Practices and Research Center, Department of Otorhinolaryngology, Samsun, Turkey

<sup>2</sup>University of Health Sciences Turkey, Samsun Health Practices and Research Center, Department of Radiation Oncology, Samsun, Turkey

<sup>3</sup>Ondokuz Mayıs University Medical Faculty, Department of Otorhinolaryngology, Samsun, Turkey

**ORCID ID:** G.A. 0000-0003-0699-6585; N.F.T. 0000-0001-6265-0058; M.D.M. 0000-0002-5613-3393; S.A. 0000-0002-1383-2215;  
A.Ö. 0000-0002-6155-5988

**Citation:** Akgul G, Turgut NF, Mehel MD, Aydogdu S, Ozgur A. Do tumor board recommendations influence the decisions of clinicians in planning the treatment of head and neck cancers? Tr-ENT 2021;31(2):39-44. <https://doi.org/10.26650/Tr-ENT.2021.40316>

## ABSTRACT

**Objective:** The aim of this study is to compare the decisions made at established tumor board meetings for planning the treatment of head and neck cancer patients with the individual treatment decisions of clinicians who attended the meetings.

**Material and Methods:** A total of 188 patients with head and neck tumors were included in this study, all of whom had been evaluated at weekly tumor board meetings at our clinic. The tumor board consisted of otolaryngologists, radiation oncologists, medical oncologists, pathologists, and radiologists. Before the board meetings, all data belonging to the patients were given to the otolaryngology surgeons and radiation oncologists who were to attend. Their treatment preferences were asked of them individually. The treatment options that clinicians recommended individually prior to board meetings were compared with the decisions made by the tumor board.

**Results:** It was observed that 34% (64 cases out of 188) of the individual decisions made by ENT surgeons and 34.6% (65 cases out of 188) of those made by radiation oncologists changed following tumor board meetings. There was a statistically significant difference between the treatment options offered individually by both ENT surgeons and radiation oncologists and the treatment recommendations made by the tumor board.

**Conclusion:** According to the data we obtained, the recommendations for treating patients with head and neck cancers made by the tumor boards may differ from the personal decisions of attending clinicians. Therefore, to make decisions that ensure the highest quality patient care, we believe it is necessary to evaluate all patients with head and neck tumors at multidisciplinary tumor board meetings regardless of cancer stage.

**Keywords:** Head and neck cancer, multidisciplinary team, tumor board

## INTRODUCTION

Head and neck cancers are among the most common malignancies in the world and encompass the lips, oral cavity, salivary glands, oropharynx, nasopharynx, larynx, hypopharynx, and skin. According to a 2018 report by the International Agency for Research on Cancer, head and neck cancers comprise the seventh most common types of cancer

with 890,000 new cases per year (1). Many factors, such as tumor stage, pathology evaluation, and patient comorbidity, are taken into account during cancer treatment. However, the differences in medical branches' clinical approaches and the varying clinical experience of doctors can impact treatment preferences, even when patient criteria are the same. As for all other malignancies for the last 30 years, tumor boards have played an important role in determining treatment

**Corresponding Author:** Gökhan Akgül E-mail: g.akgul-57@hotmail.com

**Submitted:** 07.05.2021 • **Accepted:** 02.08.2021



This work is licensed under Creative Commons Attribution-NonCommercial 4.0 International License.

modalities for head and neck malignancies (2). The diversity and experience of tumor board members, who come from many different disciplines, have proven to be more efficient in evaluating and managing disease (3).

In the past, tumor patients were referred to the relevant surgical branch and passed on to oncology departments only if necessary (4). In addition, for patients who were considered inoperable, an oncologist’s opinion was often requested regarding palliative treatment (4-6). Today, legal procedures and technological advancements in the field of chemotherapy and radiotherapy have increased the importance of a multidisciplinary approach in planning cancer patient treatment, encouraging joint decisions rather than relying solely on individual ones made by single practitioners (3, 5, 7).

St. Thomas Aquinas said, “Quia parvus error in principio magnus est in fine” (A small error at the outset is a large one in the end) (8). Given that cancer treatment is long-term, choosing an appropriate first step in the treatment process is of paramount importance. To avoid adverse conditions during treatment, it is essential to get opinions from clinicians with different specialties and to identify all relevant care opportunities before planning treatment (9). For this reason, most cancer centers decide on patient treatment at tumor board meetings, although there is no legal requirement to do this in most countries. At our tertiary center, medical specialists dealing with cancer surgery organize tumor board meetings, where clinicians share their knowledge and experience with other professionals. In this study, the effectiveness of tumor boards was investigated by comparing the individual treatment preferences of ENT surgeons and radiation oncologists with the recommendations given by tumor boards for patients diagnosed with head and neck cancers.

## MATERIALS AND METHODS

This study obtained the approval of the Samsun Research and Training Hospital Ethics committee (approval ID: 2020/0213) and evaluated the treatment modalities of patients diagnosed with head and neck cancers at our otolaryngology clinic. These cases were discussed at tumor board meetings held between January 2018 and January 2020.

At our hospital, tumor board meetings are held weekly. Board members consist of otolaryngologists, radiation oncologists, medical oncologists, radiologists, pathologists, and psychiatrists, as well as swallowing therapists, speech therapists, respiration therapists, and psychologists. Clinicians from different specialties are also invited to meetings when necessary. All patients diagnosed with head and neck cancers are discussed at the tumor board meetings regardless of cancer stage. Treatment plans are made in line with the decisions made at the meetings.

In this study, the files of all patients to be discussed at tumor board meetings containing test results, age, and gender information were provided to ENT surgeons and radiation

oncologists who regularly attended tumor board meetings. Patient names were removed from the files to avoid influencing the opinions of clinicians regarding treatment. These clinicians were then asked to choose a treatment modality for the given patient from various options, such as surgery, radiotherapy (RT), chemotherapy (CT), chemoradiotherapy (CRT), follow-ups, and additional examinations/tests (such as radiological imaging, nuclear imaging, clinical assessment, and re-biopsy). The initial treatment modalities as suggested by clinicians were compared with treatment recommendations decided by the board. The differences between these decisions were also evaluated according to tumor stage.


Patients who were to be operated on in the first tumor board were evaluated as new patients in the postoperative tumor board. Therefore, surgery and adjuvant CRT were classified separately for the same patient. However, patients who were discussed at tumor board meetings after they had completed additional tests were excluded from the study, since a consensus on their treatment was previously reached.

In statistical comparisons between groups, a t-test was used for continuously changing data, while a chi-squared test was used for discontinuous data. In all measurements, a *p*-value < 0.05 was considered statistically significant. All statistical analyses were conducted using SPSS Statistics 24.0 (IBM SPSS Statistics for Windows, NY, USA).

## RESULTS

In the 188 cases of head and neck tumors included in the study, the mean participant age was 62±11.16 years (between 25–95). 161 (85%) of the patients were male and 27 (15%) were female. The histology, regions, and stages of the evaluated tumors are outlined in Table 1.

In comparing the treatment decisions suggested by the tumor board with the individual clinician decisions, it was observed that individual ENT surgeon decisions changed in 64 cases (34%) and those of radiation oncologists changed in 65 cases (34.6%). When the rate of change according to the stages was compared, the highest was seen in stage 3 (44,4%) in ENT surgeons and in stage 2 (43,5%) in radiation oncologists (Figure 1).



**Figure 1: The rates of change of the decisions of radiation oncologists and ent surgeons according to stages.**

**Table 1: Information regarding histology, region and stage of the tumors evaluated.**

	Number of tumors evaluated (n)	Percentage (%)
<b>A. Histology</b>		
Squamous Cell Carcinoma	163	86.7
Adenocarcinoma	1	0.5
Mucoepidermoid Carcinoma	3	1.6
Neuroendocrine Tumor	2	1.1
Adenoid Cystic Carcinoma	3	1.6
Spindle Cell Carcinoma	3	1.6
Basosquamous Carcinoma	4	2.1
Carcinoma Ex Pleomorphic Adenom	1	0.5
Undifferentiated Carcinoma	4	2.1
Oncocytoma	1	0.5
Chondrosarcoma	2	1.1
Lymph Epidermal Tumor	1	0.5
<b>B. Tumor Region</b>		
Larynx	115	61.2
Hypopharynx	3	1.6
Oropharynx	6	3.2
Oral Cavity	28	14.9
Paranasal Sinuses	5	2.7
Skin	12	6.4
Nasopharynx	7	3.7
Salivary Glands	7	3.7
Neck Metastasis of Unknown Origin	5	2.7
<b>C. Tumor Stage</b>		
Stage 1	50	26.5
Stage 2	62	32.9
Stage 3	54	28.7
Stage 4	22	11.7

A comparison of the initial treatment preferences of ENT surgeons with the recommendations given by the tumor board according to tumor stage is detailed in Table 2. The rate of change in the decisions of ENT surgeons at all tumor stages was statistically significant ( $p$ -value at Stage 4=0.011,  $p$ -value at other stages <0.001).

Comparisons of the initial treatment preferences of radiation oncologists with those recommended by the tumor board based on tumor stage are provided in detail in Table 3. Similarly, the rate of change in the decisions of radiation oncologists at all tumor stages was found to be statistically significant ( $p$ -value at Stage 4 = 0.011,  $p$ -value at other stages <0.001).

## DISCUSSION

Treating head and neck cancers is a complex process that can be affected by the tumor pathology, cancer stage, and the patient's general condition (3, 7, 10). Given the diversity of treatment options, such as surgery, radiotherapy, chemotherapy or combined therapy, the role of the multidisciplinary approach in this process is significant (9, 11). In addition, after the treatment of the primary disease, the opinions of speech therapists, nutritionists, dentists, and psychologists about treating potential comorbidities are invaluable (11). For this reason, tumor boards, which enable a more practical application of the multidisciplinary approach by gathering clinicians of different specialties and allow a rapid exchange of ideas, lead to more efficient treatment decisions. It is also known that tumor boards can influence the decisions of individual specialists (4).

The compliance of decisions made at tumor board meetings with treatment preferences of individual specialists has been studied before, but research is limited about treatment decision compliance according to tumor stage in head and neck cancers. In their study, Markus et al. (2) compared tumor board decisions with the pre-meeting decisions of surgeons and oncologists about 172 head and neck cancer patients and observed changes in pre-meeting preferences for 52 patients (30%). In another study evaluating pediatric cancer patients discussed at tumor board meetings, it was shown that proposed treatment options changed following meetings in 35% of cases (12). Similar to the studies in the literature, a 34% change in proposed treatment decisions following board meetings was observed in the current study. A change over 30 percent is a significant difference. Specialists tend to prefer treatment procedures in their field of expertise. In this study, oncologists emphasized the rt option more frequently in their first choice at all stages and it was observed that surgeons preferred the ct and crt option less in their first choice. In our study, these decisions come to the fore especially at stage 2 for radiation oncologists and at stage 3 for ENT surgeons.

In Markus et al. (2), it was observed that the treatment preferences of medical or radiation oncologists were more likely to change after board meetings than those of oncology surgeons. In addition, regardless of squamous cell carcinoma or skin malignancies, the initial treatment choices of medical or radiation oncologists did not include surgical intervention, and the rate of change in their decisions after board meetings was statistically significant. The findings of the current study demonstrate that radiation oncologists initially preferred radiotherapy for early disease stages, but the rate of change in their decisions after tumor board meetings was found statistically significant.

Although the influence of tumor boards' recommendations on the individual preferences of clinicians is known, there is limited evidence for the effectiveness of these decisions on treatment outcomes (10, 13, 14). A meta-analysis in the



**Table 2: The comparison of initial treatment preferences of ENT surgeons with tumor board decisions according to tumor stage.**

Stage			Total	Tumor board recommendation					Change rates n (%)
				Surgery	RT	CRT	Follow-up	Additional test	
Stage 1	ENT surgeon preference	Surgery	11	8	3	0	0	0	3 (27.2)
		RT	28	3	22	2	0	1	6 (21.4)
		CRT	1	1	0	0	0	0	1 (100)
		Follow-up	9	2	0	0	7	0	2 (22.2)
		Additional test	1	0	0	0	0	1	0 (0)
	Total	50	14	25	2	7	2	12 (24)	
Stage 2	ENT surgeon preference	Surgery	33	28	4	1	0	0	5 (15.1)
		RT	6	0	3	2	0	1	3 (50)
		CRT	3	2	0	0	0	1	3 (100)
		Follow-up	17	1	5	0	9	2	8 (47)
		Additional test	3	1	0	0	0	2	1 (33.3)
	Total	62	32	12	3	9	6	18 (29)	
Stage 3	ENT surgeon preference	Surgery	28	17	2	7	0	2	11 (39.2)
		RT	13	3	7	3	0	0	6 (46.1)
		CRT	6	1	1	4	0	0	2 (33.3)
		Follow-up	5	0	4	0	1	0	4 (80)
		Additional test	2	0	1	0	0	1	1 (50)
	Total	54	21	15	14	1	3	24 (44.4)	
Stage 4	ENT surgeon preference	Surgery	6	4	0	2	0	0	2 (33.3)
		RT	7	0	4	3	0	0	3 (42.8)
		CRT	8	0	2	6	0	0	2 (25)
		Additional test	1	0	0	1	0	0	1 (100)
	Total	22	4	6	12	0	0	8 (36.1)	
Total	ENT surgeon preference	Surgery	78	57	9	10	0	2	21 (26.9)
		RT	54	6	36	10	0	2	18 (33.3)
		CRT	18	4	3	10	0	1	8 (44.4)
		Follow-up	31	3	9	0	17	2	14 (45.1)
		Additional test	7	1	1	1	0	4	3 (42.8)
	Total	188	71	58	31	17	11	64 (34)	

The initial preferences of ENT surgeons have changed in 64 patients (34%). ( $p=0.011$  in Stage 4,  $p<0.001$  in other stages)

literature investigating tumor board decisions over a span of approximately 20 years emphasized that the rate of change in decisions was between 4% and 45% after tumor board meetings, but there was not enough evidence to substantiate that the revised decisions led to better treatment (14). In this meta-analysis, only one study about head and neck tumors was examined, and the rate of change was reported as 27% (15). In their study, Boxer et al. (13) reviewed the outcomes of 504 lung cancer patients discussed at tumor board meetings, out of 988 patients referred to their clinic. They concluded that tumor board decisions provided treatment modalities that increased quality of life but did not alter life expectancy. Large patient cohorts and attentive planning are required to evaluate the long-term effects of individual treatment approaches and

recommendations given by tumor boards for patients with head and neck cancers.

Considering cost and treatment effectiveness, some authors argue that only advanced head and neck cancers should be discussed at tumor board meetings. In addition, they also suggest that the board recommendations for early-stage malignancies do not have significant superiority over individual clinician decisions (7, 10). Contrary to these views, the findings obtained in this study suggest that there was a statistically significant difference between the treatment approaches of tumor boards and individual specialists, including those for early-stage head and neck cancer patients.

**Table 3: The comparison of initial treatment preferences of radiation oncologists with tumor board decisions according to tumor stage.**

Stage			Total	Tumor board recommendation					Change rates n (%)
				Surgery	RT	CRT	Follow-up	Additional test	
Stage 1	Radiation oncologist preference	Surgery	10	7	3	0	0	0	3 (30)
		RT	28	5	21	1	0	1	7 (25)
		CRT	1	0	0	1	0	0	0 (0)
		Follow-up	10	2	1	0	7	0	3 (30)
		Additional test	1	0	0	0	0	1	0 (0)
		Total	50	14	25	2	7	2	13 (26)
Stage 2	Radiation oncologist preference	Surgery	14	14	0	0	0	0	0 (0)
		RT	32	16	11	2	1	2	21 (65.6)
		CRT	4	2	0	1	0	1	2 (50)
		Follow-up	12	0	1	0	8	3	4 (33.3)
		Total	62	32	12	3	9	6	27 (43.5)
Stage 3	Radiation oncologist preference	Surgery	21	15	0	5	0	1	6 (28.5)
		RT	15	3	11	1	0	0	4 (26.6)
		CRT	14	3	1	8	1	1	6 (42.8)
		Follow-up	3	0	3	0	0	0	3 (100)
		Additional test	1	0	0	0	0	1	0 (0)
		Total	54	21	15	14	1	3	19 (35.1)
Stage 4	Radiation oncologist preference	Surgery	3	2	0	1	0	0	1 (33.3)
		RT	8	0	6	2	0	0	2 (25)
		CRT	11	2	0	9	0	0	2 (18.1)
		Total	22	4	6	12	0	0	5 (22.7)
Total	Radiation oncologist preference	Surgery	48	38	3	6	0	1	10 (20.8)
		RT	83	24	49	6	1	3	34 (40.9)
		CRT	30	7	1	19	1	2	11 (36.6)
		Follow-up	25	2	5	0	15	3	10 (40)
		Additional test	2	0	0	0	0	2	0 (0)
		Total	188	71	58	31	17	11	65 (34.6)

The initial preferences of radiation oncologists have changed in 65 patients (34,6%). ( $p=0.001$  in Stage 4,  $p<0.001$  in other stages)

## CONCLUSION

This study investigated the effectiveness of tumor boards by comparing individual treatment preferences of ENT surgeons and radiation oncologists with the recommendations made in tumor boards for patients diagnosed with head and neck cancers. The aim of this study was not to evaluate the outcomes of doctors' treatment decisions, but rather to investigate the compatibility of their preferred treatment options with those of the tumor board as a whole. It should be noted that results may vary depending on individual treatment centers according to clinician experience and the clinics' technical allowances. In light of our findings, we emphasize the importance of tumor boards in practicing a multidisciplinary clinical approach and evaluating all cancer patients, including early-stage patients.

**Ethics Committee Approval:** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (University of Health Sciences Samsun Education and Research Hospital Clinical Research Ethics Committee dated 13.02.2020 and numbered 2020/0213) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed Consent:** Informed consent was obtained from all individual participants included in the study.

**Peer-Review:** Externally peer-reviewed.

**Author Contributions:** Conception/Design of Study- G.A., N.F.T., M.D.M., S.A., A.Ö.; Data Acquisition- G.A., N.F.T., M.D.M., S.A., A.Ö.; Data Analysis/Interpretation- G.A., N.F.T., M.D.M., S.A., A.Ö.;

Drafting Manuscript- G.A., N.F.T., M.D.M., S.A., A.Ö.; Critical Revision of Manuscript- G.A., N.F.T., M.D.M., S.A., A.Ö.; Final Approval and Accountability- G.A., N.F.T., M.D.M., S.A., A.Ö.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

## REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424.
2. Brunner M, Gore SM, Read RL, Alexander A, Mehta A, Elliot M, et. al. Head and Neck Multidisciplinary Team Meetings: Effect on Patient Management. *Head Neck* 2015;37(7):1046-50.
3. Eskander A, Irish J, Groome PA, Freeman J, Gullane P, Gilbert R, et al. Volume-outcome relationships for head and neck cancer surgery in a universal health care system. *Laryngoscope* 2014;124:2081-8.
4. Bozec A, Culi e D, Poissonnet G, Dassonville O. Current role of primary surgical treatment in patients with head and neck squamous cell carcinoma. *Curr Opin Oncol* 2019;31(3):138e145.
5. Lee VHF, Chan JYW, Vardhanabhuti V, Kwong DLW, Leung TW, Chan SY, et al. Advancing Care for Head and Neck Cancers in a Multidisciplinary Tumour Board in the East. *Clin Oncol (R Coll Radiol)* 2019;31(8):549-59.
6. Guy JB, Benna M, Xia Y, Dagenet E, Ben Mrad M, Jmour O, et al. Quality Insurance in Head and Neck Cancer Multidisciplinary Team Meetings: A Watchful Eye on Real-Life Experience. *Oral Oncol* 2019;91:35-8.
7. Nguyen NP, Vos P, Lee H, Borok TL, Karlsson U, Martinez T, et al. Impact of Tumor Board Recommendations on Treatment Outcome for Locally Advanced Head and Neck Cancer. *Oncology* 2008;75(3-4):186-91.
8. Aquinas T. Prologue. In: *On being and essence*. Pontifical Institute on Mediaeval Studies; 1968. p.1. Translated by Armand Maurer.
9. Westin T, Stalfors J. Tumour boards/multidisciplinary Head and Neck Cancer Meetings: Are They of Value to Patients, Treating Staff or a Political Additional Drain on Healthcare Resources? *Curr Opin Otolaryngol Head Neck Surg* 2008;16(2):103-7.
10. Mullan BJ, Brown JS, Lowe D, Rogers SN, Shaw RJ. Analysis of Time Taken to Discuss New Patients With Head and Neck Cancer in Multidisciplinary Team Meetings. *Br J Oral Maxillofac Surg* 2014;52(2):128-33.
11. Haddad R, Annino D, Tishler RB. Multidisciplinary approach to cancer treatment: focus on head and neck cancer. *Dent Clin North Am* 2008;52(1):1-17.
12. Thenappan A, Halaweish I, Mody RJ, Smith EA, Geiger JD, Ehrlich PF, et.al. Review at a Multidisciplinary Tumor Board Impacts Critical Management Decisions of Pediatric Patients With Cancer. *Pediatr Blood Cancer* 2017;64(2):254-8.
13. Boxer MM, Vinod SK, Shafiq J, Duggan KJ. Do Multidisciplinary Team Meetings Make a Difference in the Management of Lung Cancer? *Cancer* 2011;117(22):5112-20.
14. Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et. al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. *Cancer Treat Rev* 2016;42:56-72.
15. Wheless SA, McKinney KA, Zanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. *Otolaryngol Head Neck Surg* 2010;143(5):650-4.

# Validation of the Turkish Translation of the Facial Clinimetric Evaluation Scale in Patients with Peripheral Facial Paralysis

Ağah Yeniçeri<sup>1</sup> , Fakih Cihat Eravcı<sup>2</sup> , Mücahit Yalçın<sup>3</sup> , Hakan Tutar<sup>3</sup> 

<sup>1</sup>Ministry of Health Kırşehir Education and Research Hospital, Department of Otorhinolaryngology, Kırşehir, Turkey

<sup>2</sup>Necmettin Erbakan University, Meram Medical Faculty, Department of Otorhinolaryngology, Konya, Turkey

<sup>3</sup>Gazi University, Faculty of Medicine, Department of Otorhinolaryngology, Ankara, Turkey

ORCID ID: A.G. 0000-0002-5024-4009; F.C.E. 0000-0001-9092-7923; M.Y. 0000-0002-2083-1827; H.T. 0000-0001-5585-5282

**Citation:** Yeniçeri A, Eravcı FC, Yalçın M, Tutar H. Validation of the Turkish translation of the facial clinimetric evaluation scale in patients with peripheral facial paralysis Tr-ENT 2021;31(2):45-50. <https://doi.org/10.26650/Tr-ENT.2021.952546>

## ABSTRACT

**Objective:** To transcribe and validate the Facial Clinimetric Evaluation (FaCE) scale to be able to use it in a Turkish-speaking patient population with peripheral facial paralysis (PFP).

**Material and Methods:** The original English FaCE scale was translated according to international guidelines. Then a validation study was conducted on 37 patients with facial paralysis. The patients completed the scale twice at a 1-week interval. Internal consistency was evaluated with the Cronbach alpha coefficient. The correlations between the FaCE scale and the House-Brackmann Grading System (HBGS), the Sunnybrook Grading System (SBGS), and the Facial Disability Index (FDI) scores and structure validity were evaluated by calculating the Spearman rho correlation coefficient.

**Results:** The FaCE scale showed internal consistency with an excellent Cronbach  $\alpha$  value of 0.828. Test-retest reliability was shown with an Intraclass Correlation Coefficient (ICC) in the range of 0.51-0.95. The FaCE scale was determined to be well correlated with the HBGS and SBGS points ( $r=-0.51$ ,  $r=0.65$ , respectively). The FaCE scale face movement score showed the highest correlation with HBGS ( $r=-0.61$ ). SBGS had the highest correlation with the oral function score ( $r=0.61$ ). The study determined there to be a good correlation between the FaCE scale and the social/well-being function and physical function of the FDI ( $r=0.69$ ,  $r=0.66$ , respectively).

**Conclusion:** The FaCE scale is a reliable and valid tool for assessing the quality of life of PFP patients. The Turkish version of the FaCE Scale showed good psychometric properties. By showing high validity and reliability, the Turkish FaCE scale can be used in Turkish-speaking patients with peripheral facial paralysis.

**Keywords:** Translation, facial clinimetric evaluation scale, validation, quality of life, facial paralysis

## INTRODUCTION

Peripheral facial paralysis (PFP), most frequently seen as idiopathic, is paralysis of the facial nerve that develops associated with infection, trauma, malignancy and iatrogenic etiological causes (1). The annual incidence of PFP in the general population varies between 20 and 32 per 100.000 (2). Different treatment methods can be used for the elimination of functional problems in PFP, primarily corticosteroids, antivirals (ac iclovir) and surgery (1, 2).

Patients with facial paralysis may have symptoms such as facial asymmetry, weakness of facial muscles, inability to fully

close the eyes with associated ophthalmic injuries, difficulties in eating, drinking, and talking, reduced sense of taste, and synkinesis. In addition to these functional problems, a series of psychosocial outcomes such as social isolation and depression can emerge with PFP (3). Therefore, to be able to comprehensively evaluate patients with facial paralysis, the psychosocial status and the effect of that on quality of life (QoL) must be taken into consideration together with functional problems.

It is difficult to evaluate QoL in PFP patients. Currently, there is confusion related to clinician-based scales evaluating QoL

**Corresponding Author:** Ağah Yeniçeri E-mail: [agah\\_yeniceri@hotmail.com](mailto:agah_yeniceri@hotmail.com)

**Submitted:** 16.06.2021 • **Accepted:** 05.08.2021



This work is licensed under Creative Commons Attribution-NonCommercial 4.0 International License.

and several patient-based evaluation scales. Of these, the House-Brackmann Grading System (HBGS) and the Sunnybrook Facial Grading System (SBGS) are the most used clinician-based evaluation systems (4, 5). Although these determine the anatomic and physiological severity of facial paralysis (3), they do not consider the effect of PFP on QoL. The Facial Clinimetric Evaluation Scale (FaCE) (6) and the Facial Disability Index (FDI) (7), which are used for the evaluation of QoL in PFP patients, are patient-based QoL scales which are well known by clinicians, easy to use, and have proven validity and reliability (8, 9). Since they were first created, these scales have been used in many international clinical studies (3, 8-10).

The FDI provides an evaluation of the feelings about the mouth, eyes and other facial features, and the effects of these on QoL (7). The FaCE scale includes 15 questions. The 6 sub-dimensions comprise facial movements, social function, facial comfort, lacrimal control, eye comfort, and oral function. The total points and affected area points range from 0 (worst) to 100 (best) (6).

Following use of the original English versions, the FaCE and FDI scales have been translated and approved for use in several languages, such as French, Spanish, Italian, German, Chinese, Dutch, and Swedish (11-17). Only the FDI has been translated and approved in the Turkish language (18). The purpose of this study was to form and validate the Turkish model of the FaCE scale for a Turkish-speaking population.

## MATERIALS AND METHODS

### Ethics

The study was approved by the Ethics Working Group for Scale Evaluation of Gazi University (Approval no: 2019-361). We obtained permission for this study by interviewing the authors of the English original of the FaCE scale. This study was conducted in two stages, first as a pilot study with the translation of the FaCE scale from English to Turkish, then in the second stage as validation in a PFP patient community.

### Translation

The translation process was implemented according to the internationally accepted recommendations for the translation and cross-cultural adaptation of health-related quality of life scales (19, 20). The original English FaCE scale was translated into Turkish independently by two ear, nose, and throat specialists, both of whom were native Turkish speakers and had an excellent level of English. Then the two versions were examined by a committee that was participating in the study, and consensus was reached. The Turkish model was then independently translated back into English by two English native-speaker translators, both of whom had an excellent level of Turkish. The aim of this back-translation was to determine any differences in consistency and context between the original model and the back-translated Turkish version. A professional medical translator then compared the back translations with the original English FaCE. As a result of this, there were no differences in meaning or any inconsistency detected, and the

Turkish version of the FaCE was approved. Finally, a pilot test was conducted on 5 patients with PFP and 5 healthy individuals, all of whom were native Turkish speakers. These 10 subjects completed the Turkish version of FaCE under the supervision of one of the researchers. No differences or problems were determined in respect of reading, understanding or responding to the scale items, and so no changes were made to the Turkish version of the FaCE scale.

### Questionnaires

The FDI, developed by Van Swearingen et al in 1996, is a QoL scale (7), which was translated into Turkish in 2020 (18). It consists of two areas, social/well-being function and physical function. It contains 10 Likert type questions in total. The social/well-being function points interval from 0 (worst) to 100 (best) and the physical function points interval from -25 (worst) to 100 (best).

The FaCE scale, developed by Khan et al in 2001, is a PFP-related QoL scale (6). It includes 15 items with responses on a 5-point Likert scale, in 6 sub-dimensions: facial movements, social function, facial comfort, lacrimal control, eye comfort, and oral function. The total points and affected area points range from 0 (worst) to 100 (best) (6).

### Validation

This study was conducted with 37 patients with PFP in the Ear, Nose, and Throat (ENT) Clinic of Gazi University Medical Faculty Hospital between November 2019 and June 2020. The patients included were aged >18 years, were able to read and write in Turkish, and had a diagnosis of unilateral PFP ongoing for at least 3 months. Patients were not included from the study if they had poor cognitive functions, were illiterate, had temporary PFP (Bell's Palsy), bilateral facial paralysis or if they refused to sign the consent form.

Demographic data of the patients such as age, gender, etiology, and duration of paralysis were obtained from the patient and hospital medical records. The severity of PFP was evaluated with the HBGS and SBGS (4, 5). HBGS is a clinician-based system that evaluates facial function, in which PFP is graded from I (normal) to IV (total paralysis) (4). The SBGS is a system which evaluates symmetry at rest, involuntary movement symmetry, and synkinesis. At the end of the evaluation, a total point is determined through comparison with the normal side, ranging from 0 (total paralysis) to 100 (normal function) (5).

All the patients included in the study provided signed informed consent. The patients completed the Turkish FaCE scale and FDI. For test-re test reliability, the same patients completed the FaCE scale again after a 1-week interval. During that period of one week, no treatment was applied to the patients.

### Statistical analysis

Statistical analysis was performed using the software program SPSS version 22.0 for Windows (IBM Corp. Armonk, NY). Descriptive statistics were analyzed to identify patient characteristics. Correlations between the Turkish FaCE scale

**Table 1: Patient Characteristics.**

Patient Characteristic		N	%	Mean	SD	Median	Range
Gender	Female	13	35.1				
	Male	24	64.9				
Age (years)				47.35	16.104	52	18-70
Side	Left	18	48.6				
	Right	19	51.4				
Duration of PFP (months)				85.84	105.812	60	3-480
Etiology	Acoustic neuroma	10	27.0				
	Trauma	5	13.6				
	Iatrogenic	6	16.2				
	Tumors	6	16.2				
	Other	10	27.0				
HBGS				4.16	1.191	5	2-6
SBGS				35.84	18.811	30	9-91

SD: Standard Deviation, HBGS: House-Brackmann Grading System, SBGS: Sunnybrook Grading System

points and the HBGS, SBGS, and FDI scores, and the internal consistency were evaluated by calculating the Spearman's Rho Correlation coefficient ( $r$  value). Cronbach's  $\alpha$  coefficient was calculated to evaluate the internal consistency of the items in the FaCE scale. A Cronbach  $\alpha$  worth of  $>0.8$  is recommended but  $\alpha >0.7$  is acceptable (21). The test-re test reliability was analyzed with the Intraclass Correlation Coefficient (ICC). A worth of  $p < 0.05$  was admitted as statistically significant.

## RESULTS

### Validation

This prospective study, conducted between November 2019 and June 2020, included a total of 37 patients comprising 13 (35%) females and 24 (65%) males, with an average age of  $47.35 \pm 16.1$  years (range, 18-70 years). All the patients completed the Turkish versions of the FaCE and FDI. Unilateral PFP was determined on the right side in 19 (51.4%) patients and on the left side in 18 (48.6%). The mean duration of PFP was  $85.8 \pm 105.8$  months (range, 3-480 months). The most common etiological cause was acoustic neuroma at the rate of 27%. The mean SBGS points were determined to be  $35.84 \pm 18.8$  (median:30) and the mean HBGS points to be  $4.16 \pm 1.19$  (median:5) (Table 1).

The baseline (D0) and 7<sup>th</sup> day (D7) total and sub-domain scores of the FaCE and the FDI scores of the patients are shown in Table 2.

### Internal consistency and reliability

Internal consistency was tested with the Cronbach  $\alpha$  coefficient, which was calculated to show an excellent value at 0.828. Points in the range of 0.67 to 0.81 were calculated for the sub-domains of the FaCE scale. The test-re test reliability was shown with ICC values ranging from 0.51 to 0.95 (Table 3).

Correlations between the FaCE scale and the HBGS, SBGS, and FDI points were calculated with the Spearman coefficient. A good correlation was determined between FaCE and the HBGS and SBGS points ( $r = -0.51$ ,  $r = 0.65$ , respectively). The correlation with

**Table 2: Facial Clinimetric Evaluation (FaCE) scale and Facial Disability Index (FDI) scores.**

D0 (n=37)	Mean	SD	Median	Range
<b>FDI</b>				
Physical function	68.11	19.38	70	30-95
Social/Well-being function	74.59	19.65	80	16-100
<b>FaCE Scale</b>				
Facial movement	21.82	24.71	8.3	0-91.6
Facial comfort	66.87	26.1	58.3	0-100
Oral function	68.58	29.41	75	0-100
Eye comfort	51.12	35.20	50	0-100
Lacrimal control	66.35	32.65	75	0-100
Social function	77.03	24.65	87.5	6.25-100
Total	58.97	17.22	60	16.6-95
<b>D7 (n=37)</b>				
<b>FaCE Scale</b>				
Facial movement	28.11	23.11	16.6	0-83.3
Facial comfort	63.93	24.13	58.3	25-100
Oral function	66.22	29.59	62.5	0-100
Eye comfort	52.70	35.00	50	0-100
Lacrimal control	65.74	32.06	75	0-100
Social function	81.42	22.70	87.5	12.5-100
Total	60.56	17.43	60	15-96.6

SD: Standard Deviation, D0: Day 0, D7: Day 7

**Table 3: Test-Retest Reliability and Internal Consistency of the FaCE scale.**

	Internal consistency Cronbach's $\alpha$		Test - Retest	
	Test	Retest	ICC	%95 CI
Total	0.828	0.836	0.950	0.903 – 0.974
Facial movement score	0.800	0.709	0.862	0.719 – 0.931
Facial comfort score	0.812	0.775	0.905	0.817 – 0.951
Oral function score	0.673	0.726	0.953	0.909 – 0.976
Eye comfort score	0.672	0.671	0.939	0.881 – 0.968
Lacrimal control	*	*	0.519	0.054 – 0.754
Social function	0.769	0.832	0.816	0.645 – 0.905

CI: confidence interval, ICC: intraclass correlation coefficient, \*Cronbach's  $\alpha$  could not be calculated for only one item on the scale

**Table 4: Correlations between the FaCE scale scores and the House-Brackmann, Sunnybrook, and FDI scores.**

FaCE	HBGS (n=37)	SBGS (n=37)	FDI Physical function (n=37)	FDI Social/Well-being function (n=37)
Facial movement score	-0.612**	0.508**	0.287	0.410*
Facial comfort score	-0.274	0.293	0.455**	0.310
Oral function score	-0.461**	0.613**	0.839**	0.428**
Eye comfort score	-0.242	0.291	0.369*	0.373*
Lacrimal control	-0.116	0.225	0.251	-0.066
Social function	-0.242	0.410*	0.379*	0.696**
Total	-0.510**	0.651**	0.692**	0.663**

\*p<0.05, \*\*p<0.01

HBGS was negative due to the design of the HBGS. The facial movement score of the FaCE scale showed the highest correlation with HBGS ( $r=-0.61$ ). The SBGS had the highest correlation with the oral function score of the FaCE scale ( $r=0.61$ ). There was a good correlation between the FaCE scale and the social/well-being function and physical function of the FDI ( $r=0.66$ ,  $r=0.69$ , respectively). The FDI physical function had the highest correlation with the oral function score of the FaCE ( $r=0.83$ ) and the FDI social/well-being function had the highest correlation with the social function score of the FaCE ( $r=0.69$ ) (Table 4).

## DISCUSSION

This study was conducted for validation of the FaCE scale, the Turkish version of which was created. The translation into Turkish and inter-cultural adaptation was performed in accordance with international literature (19). No difficulties were encountered in the translation and adaptation process. As far as we know, our study is the first study to have translated the FaCE scale into Turkish and provided validation. Patients with temporary PFP, which can recover rapidly, primarily Bell's palsy, were excluded from the study.

PFP has a negative effect on the psychosocial status of patients, communication, and quality of life. Patients with severe PFP may show more severe physical disability, but may not experience more social disabilities or psychological problems (22). The effect of PFP on the QoL of the patient cannot be

estimated by the level of the facial paralysis (23-25). In a systematic examination of the results of patient-based scales, Ho et al reported that the inclusion and exclusion criteria of 3 scales corresponded specifically to facial paralysis. Of these, the FaCE scale and FDI were accepted as valid for peripheral facial paralysis patients, and the FaCe scale was seen to meet all psychometric standards (23).

The Turkish FaCE scale had Cronbach  $\alpha$  values of 0.828 and 0.836 (test and re test) for internal consistency. These values showed excellent internal consistency, which was in accordance with findings in literature when compared with German, Chinese, Dutch, French, and Spanish versions (11-14, 17). The only item for which Cronbach  $\alpha$  could not be calculated was lacrimal control. All the patients completed the questionnaire on D7, so there was no loss to follow-up in the study. The ICC value for the Turkish FaCE scale showed good reliability with sub-domain and total points of 0.95-0.52.

A good correlation was determined between the Turkish FaCE scale and SBGS and HBGS ( $r=0.65$ ,  $r=-0.510$ , respectively). The FaCE scale facial movement score had the highest correlation with HBGS ( $r=0.612$ ). These results were consistent with the original English FaCE scale results, developed by Khan et al ( $r=0.55$ ,  $r=0.69$ , respectively). There was a good correlation between the facial movement score of the FaCE and the SBGS ( $r=0.508$ ). However, in contrast to findings in the literature, the highest correlation was seen to be with oral function (6, 12, 15).

The correlations between the FaCE scale and the FDI social function and physical function were determined to be at a good level ( $r=0.66$ ,  $r=0.69$ , respectively). The highest correlation was seen between the oral function score of the FaCE scale and the FDI physical function score ( $r=0.839$ ), which was consistent with the results of the original English version (6). This correlation could be due to the fact that 4 of the 5 questions in the FDI physical function domain are related to oral function (15). The FaCE scale social function score showed the highest correlation with the FDI social function score ( $r=0.696$ ), consistent with the literature (6, 13-15).

The mean values of the total and sub domain scores of the Turkish FaCE scale were determined to be higher compared to values in the literature (12, 13, 26). The reason for this could be attributed to the long duration of PFP (mean: 85.5 months, range: 3-480 months) and patients accepting their current status as etiologically permanent facial paralysis, which enabled adaptation and better tolerance of the psychosocial effects of PFP.

FaCE is the most widely used and most important of the QoL scales in patients with peripheral facial paralysis. It has also been used for various international academic studies (9, 23, 27). The FDI only evaluates two areas, the social function and physical function (7), whereas the FaCE scale evaluates a much broader area in which there could be negative effects of PFP (6). Therefore, in addition to QoL evaluation, the FaCE scale is of guidance in determining the problems of the patient. For example, a patient with a low oral function score can be referred to a clinician for precautions to be taken on this subject in the future. The reliable and valid Turkish FaCE scale will fill the gap that has been felt in the Turkish-speaking PFP patient population in respect to the evaluation and follow up of patients and referral to clinicians.

A limitation of this study was the relatively low number of patients in the study population compared to the literature (6, 11-13). This was due to the exclusion of patients who could show rapid healing, such as those with Bell's palsy, as this could have created great differences in the scale scores.

## CONCLUSION

The FaCE scale is a patient-based, reliable and valid tool which evaluates quality of life. The Turkish FaCE scale, showing high validity and reliability, can be used for Turkish-speaking patients with facial paralysis. Therefore, this study can be considered to have paved the way for the use of FaCE not only for patient evaluation and follow up but also in Turkish clinical studies.

**Acknowledgements:** We would like to thank Dr. Richard E. Gliklich for his permission to use the FaCE Scale.

**Ethics Committee Approval:** The study was approved by the Ethics Working Group for Scale Evaluation of Gazi University (Approval no: 2019-361).

**Informed Consent:** We obtained permission for this study by interviewing the authors of the English original of the FaCE scale.

**Peer-Review:** Externally peer-reviewed.

**Author Contributions:** Conception/Design of Study- A.Y., F.C.E., H.T.; Data Acquisition- A.Y., M.Y.; Data Analysis/Interpretation- A.Y., M.Y.; Drafting Manuscript- A.Y., F.C.E.; Critical Revision of Manuscript- F.C.E., H.T.; Final Approval and Accountability- A.Y., F.C.E., H.T.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

## REFERENCES

- Owusu JA, Stewart CM, Boahene K. Facial Nerve Paralysis. *Med Clin North Am* 2018;102(6):1135-43.
- Lorch M, Teach SJ. Facial nerve palsy: etiology and approach to diagnosis and treatment. *Pediatr Emerg Care* 2010;26(10):763-9; quiz 70-3.
- Luijmes RE, Pouwels S, Beurskens CH, Kleiss IJ, Siemann I, et al. Quality of life before and after different treatment modalities in peripheral facial palsy: A systematic review. *Laryngoscope* 2017;127(5):1044-51.
- House JW, Brackmann DE. Facial nerve grading system. *Otolaryngol Head Neck Surg* 1985;93(2):146-7.
- Ross BG, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. *Otolaryngol Head Neck Surg* 1996;114(3):380-6.
- Kahn JB, Gliklich RE, Boyev KP, Stewart MG, Metson RB, et al. Validation of a patient-graded instrument for facial nerve paralysis: the FaCE scale. *Laryngoscope* 2001;111(3):387-98.
- VanSwearingen JM, Brach JS. The Facial Disability Index: reliability and validity of a disability assessment instrument for disorders of the facial neuromuscular system. *Phys Ther* 1996;76(12):1288-98; discussion 98-300.
- Györi E, Przystrzelski C, Pona I, Hagmann M, Rath T, et al. Quality of life and functional assessment of facial palsy patients: A questionnaire study. *Int J Surg* 2018;55:92-7.
- Tavares-Brito J, van Veen MM, Dusseldorp JR, Bahmad F, Jr., Hadlock TA. Facial Palsy-Specific Quality of Life in 920 Patients: Correlation With Clinician-Graded Severity and Predicting Factors. *Laryngoscope* 2019;129(1):100-4.
- Bruins TE, van Veen MM, Mooibroek-Leeuwerke T, Werker PMN, Broekstra DC, et al. Association of Socioeconomic, Personality, and Mental Health Factors With Health-Related Quality of Life in Patients With Facial Palsy. *JAMA Otolaryngol Head Neck Surg* 2020;146(4):331-7.
- Garcia-Iza L, Chiesa-Estomba CM, Rosell-Romero N, Ibarguren-Esnal E, Soriano-Reixach M, et al. Translation and Validation of the Facial Clinimetric Evaluation Scale to Spanish. *Otolaryngol Head Neck Surg* 2020;194599820969622.
- Barry P, Mancini J, Alshukry A, Salburgo F, Lavieille JP, et al. Validation of French versions of the Facial Disability Index and the Facial Clinimetric Evaluation Scale, specific quality of life scales for peripheral facial palsy patients. *Clin Otolaryngol* 2019;44(3):313-22.
- Kleiss IJ, Beurskens CH, Stalmeier PF, Ingels KJ, Marres HA. Quality of life assessment in facial palsy: validation of the Dutch Facial Clinimetric Evaluation Scale. *Eur Arch Otorhinolaryngol* 2015;272(8):2055-61.



14. Volk GF, Steigerwald F, Vitek P, Finkensieper M, Kreysa H, et al. [Facial Disability Index and Facial Clinimetric Evaluation Scale: validation of the German versions]. *Laryngorhinootologie* 2015;94(3):163-8.
15. Marsk E, Hammarstedt-Nordenvall L, Engström M, Jonsson L, Hultcrantz M. Validation of a Swedish version of the Facial Disability Index (FDI) and the Facial Clinimetric Evaluation (FaCE) scale. *Acta Otolaryngol* 2013;133(6):662-9.
16. Pavese C, Cecini M, Camerino N, De Silvestri A, Tinelli C, et al. Functional and social limitations after facial palsy: expanded and independent validation of the Italian version of the facial disability index. *Phys Ther* 2014;94(9):1327-36.
17. Li Y, Jiang H, Wang K, Feng GD, Ding XY, et al. [Quality of life survey on patients with peripheral facial paralysis by using Chinese version of the FaCE scale]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2013;48(1):11-6
18. Özden F, Karaman ÖN, Tuğay N, Savaş Ö, Sözen T, et al. The reliability and validity of the Turkish version of the Facial Disability Index. *Disabil Rehabil* 2020:1-10.
19. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. *J Clin Epidemiol* 1993;46(12):1417-32.
20. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. *Spine (Phila Pa 1976)* 2000;25(24):3186-91.
21. Field A. *Discovering statistics using IBM SPSS statistics*: sage; 2013
22. Díaz-Aristizabal U, Valdés-Vilches M, Fernández-Ferreras TR, Calero-Muñoz E, Bienzobas-Allué E, et al. Correlations between impairment, psychological distress, disability, and quality of life in peripheral facial palsy. *Neurologia* 2019;34(7):423-8.
23. Ho AL, Scott AM, Klassen AF, Cano SJ, Pusic AL, Laeken NV. Measuring quality of life and patient satisfaction in facial paralysis patients: a systematic review of patient-reported outcome measures. *Plast Recons Surg* 2012;130(1):91-9.
24. Cross T, E. Sheard C, Garrud P, Nikolopoulos TP, O'Donoghue GM. Impact of facial paralysis on patients with acoustic neuroma. *Laryngoscope* 2000;110(9):1539-42.
25. Lee J, Fung K, Lownie SP, Parnes LS. Assessing impairment and disability of facial paralysis in patients with vestibular schwannoma. *Arch Otolaryngol Head Neck Surg* 2007;133(1):56-60.
26. Tavares-Brito J, Fonseca ACO, Torres RP, van Veen MM, Greene J, et al. Facial Clinimetric Evaluation Scale and Synkinesis Assessment Questionnaire Translation into Brazilian Portuguese: A Validation Study. *Int Arch Otorhinolaryngol* 2020;24(1):e24-30.
27. Ng JH, Ngo RY. The use of the facial clinimetric evaluation scale as a patient-based grading system in Bell's palsy. *Laryngoscope*. 2013;123(5):1256-60.

# Nasal Reconstruction Using Tissue Expander and Modified Paramedian Forehead Flap Supported by Cartilage Graft

Pauline Yap<sup>1</sup> , Nurul Syazana Mohamad Shah<sup>2</sup> , Arman Zaharil Mat Saad<sup>3</sup> ,  
Wan Azman Wan Sulaiman<sup>2</sup> , Siti Fatimah Noor Mat Johar<sup>2</sup> 

<sup>1</sup>Universiti Malaysia Sabah, Department of Surgery, Faculty of Medicine Health Sciences, Kota Kinabalu, Sabah, Malaysia

<sup>2</sup>Universiti Sains Malaysia, Health Campus, School of Medical Sciences, , Reconstructive Sciences Unit, Kubang Kerian, Kelantan, Malaysia

<sup>3</sup>Plastic and Reconstructive Unit, MSU Medical Centre, Management and Science University, Shah Alam, Selangor, Malaysia

**ORCID ID:** P.Y. 0000-0002-2228-3473; N.S.M.S. 0000-0001-6731-9962; A.Z.M.S. 0000-0002-4003-6783; W.A.W.S. 0000-0002-0600-9765; S.F.N.M.J. 0000-0003-4120-4918

**Citation:** Yap P, Shah NSM, Saad AZM, Sulaiman WAW, Mat Johar SFN. Nasal reconstruction using tissue expander and modified paramedian forehead flap supported by cartilage graft. Tr-ENT 2021;31(2):51-8. <https://doi.org/10.26650/Tr-ENT.2021.18480>

## ABSTRACT

This is an interesting case of a male patient with traumatic nasal injury with partial nasal amputation who was referred to our centre 3 months after the initial trauma. The wound was complicated with necrosis, the amputated nose had fallen off and a scar had formed at the wound bed. The nasal defect was greater than 2.5cm in length. More than 50% of the nose had fallen off including the bilateral alar lobule, the tip and the dorsal part of the nose. We utilized a tissue expander to create more tissue on the forehead in view of the patient's short forehead, for donor site closure and to lengthen our flap. We performed a modified paramedian forehead flap with a widened distal portion of flap, in a two-staged nasal reconstruction surgery supported by L-strut cartilage graft harvested from the 7<sup>th</sup> rib. In this report we provide an illustrative description of the procedure, its cosmetic and functional outcome and we also share the challenges we faced.

**Keywords:** Nasal reconstruction, traumatic nasal injury, rhinoplasty

## INTRODUCTION

The human nose which is situated at the centre of the face in a prominent form makes it vulnerable to trauma and cutaneous malignancy. These conditions often result in a distorted facial appearance that requires nasal reconstruction. The aesthetic and functional results of a nasal reconstruction depends on a surgeon's ability to imagine the nasal structural defect in a three-dimensional figure. This is important for the proper assessment of the defect and subsequently reconstruct the nasal deformity. The aim was to minimize deformities, scarring, and obtain good functional aesthetic outcomes based on 3 components: lining, support, and coverage.

Nasal reconstruction can be achieved with different surgical methods depending on the degree of tissue loss and the affected nasal subunits, though out of all of these methods,

the forehead flap is the gold standard. The first person who described the traditional median forehead flap was Sushruta Samhita, an ayurvedic physician from ancient India 600 B.C. (1). Later, Millard designed the paramedian forehead flap, excluding the central glabellar skin with the advantage of reduced morbidity and maintained viability (2). In our case, we described a two-staged nasal reconstruction with a modified paramedian forehead flap and used a tissue expander to create a longer and wider flap for closing both donor site and nasal defect.

## CASE REPORT

A 23-year-old gentleman was involved in a road traffic accident. He sustained partial nasal amputation. The laceration was closed primarily. However, the partially amputated nose was complicated with necrosis and treated conservatively. The amputated nose had fallen off and a scar had formed at the

**Corresponding Author:** Nurul Syazana Mohamad Shah **E-mail:** syazanashah@usm.my

**Submitted:** 16.05.2021 • **Accepted:** 05.06.2021



This work is licensed under Creative Commons Attribution-NonCommercial 4.0 International License.

wound bed which caused nasal valve contracture and partial stenosis. He underwent nasal dilatation and was on a nasal stent.

The nasal defect was greater than 2.5cm in length. There was >50% of nasal tissue loss involving bilateral alar lobule, soft triangles, tip of nose complete loss, and the dorsum. Nasal lining and columella were not injured (Figure 1A). His forehead skin was expanded using a tissue expander. The tissue expander was filled until 300cc progressively prior to his first stage surgery. The amount of water injected was based on pain and capillary refilling time. It took 3 months to achieve adequate forehead expansion.

### SURGICAL TECHNIQUE

Nasal subunits were drawn on the defect and the shape of the new nose was drawn using a sterile paper based on the size of the defect. Incision was made at the superior edge of the scar tissue along the bilateral alar rim to facilitate folding of lining component over the alar rim cartilage graft by turning down the flap to form inner lining of the nostril (Figure 1C). The paramedian forehead flap was based on the right supratrochlear artery. The artery and two branches were identified by doppler at the superior orbital rim, also the

pivot point, to provide accuracy. Based on the location of the perforator, a seagull-shape forehead flap was designed. The flap was drawn with its base over the neck of the seagull and gradually widened to the distal part, resembling a seagull's body (Figure 1C,1D). The pedicle was centred on the flap to minimize post-operative flap congestion. Incision was made to remove the tissue expander (Figure 1D). The flap was raised distally. Subgaleal dissection was proceeded until the flap was raised 3 cm from the supraorbital rim. Subsequently, subperiosteal elevation was done to incorporate the periosteal branch of the supratrochlear artery in the pedicle.

L-shaped cartilage was harvested from the 7<sup>th</sup> rib. It was cut into a L-strut 4(L) x 2.5(H) cm for dorsal support and 3cm thin slits cartilage for bilateral alar support. They were sutured into place with Prolene® 6-0. The flap was rotated laterally without tension and sutured to the defect refashioned contour with Nylon 6-0 (Figure 1B). We moulded the flap on the drawing on the paper and resurfaced the nose from nasal tip to the dorsum and left alar lobule. The donor site was closed primarily with the lax skin created by the tissue expander. Additionally, adequate full-thickness skin graft (FTSG) was obtained from the excess skin on the forehead to cover the raw area over the flap's pedicle.



**Figure 1.** The process of nasal reconstruction. A. The initial nasal defect was greater than 2.5cm in length. There was >50% of nasal tissue loss involving bilateral alar lobule, soft triangles, tip of nose and dorsum complete loss. The nasal lining and columella remained intact. B. The flap was rotated laterally without tension and sutured to the defect refashioned contour. C. Incision was made at the superior edge of the scar tissue along the bilateral alar rim to facilitate folding of lining component over the alar rim cartilage graft by turning down the flap to form inner lining of the nostril. D. A seagull-shape forehead flap was designed. The flap was drawn with its base over the neck of the seagull and gradually widened to the distal part, resembling a seagull's body. Incision was made to remove the tissue expander.



**Figure 2.** After 2 months, the pedicle was divided creating an inverted-V at the base. The edge of the flap was refashioned. Small portion of the superior flap edge was complicated with necrosis. There was contracture over right alar lobule. The patient underwent refashioning of flap edge and FTSG.

After two months, the pedicle was divided creating an inverted-V at the base. The edge of the flap was refashioned. Small portion of the superior flap edge was complicated with necrosis, which was treated by refashioning of the flap edge and FTSG three weeks later. One month after the flap refashioning, the flap edges were healed (Figure 2). The right side of the flap was slightly bulky. There was contracture over the right alar lobule. The patient would be subjected to further surgery to reconstruct the right alar lobule. Overall, the shape of the reconstructed nose is satisfactory.

## DISCUSSION

Nasal reconstruction is one of the most complex types of reconstruction surgery of the face. The nose, as a three-dimensional structure at the centre of the face means that it is often the main focus of attention for the patient and also the public (3). Therefore, it is difficult to achieve patient's satisfactory on aesthetic outcome. Correa et al. stated that a defect size more than 2 cm wide in the horizontal plane or with exposed bone and/or cartilage were best repaired with paramedian forehead flap (3). Therefore, the gold standard paramedian forehead flap was the most suitable choice of nasal reconstruction in our case. The defect size was great and the forehead skin provided the closest texture to nasal tissue. The only pitfall the surgeon should carefully handle is the approximation of the vertical wound over the forehead caused by the secondary defect. A meticulous wound closure technique is crucial to minimize wound tension that cause scarring (4).

In patients with shortened vertical forehead height, the inclusion of scalp skin in the flap should be avoided due to the difference of texture and colour of the nasal skin (5,6). Our patient had a short forehead. The use of a tissue expander gave several advantages. It provided sufficient hairless length for the flap, enabled primary closure at the donor site without tension, provided extra tissue for FTSG and left an inconspicuous scar on the forehead. In addition, the expanded flap has the advantage of decreased thickness in which accurate reconstruction in two stages was permissible. Therefore, the three stage reconstruction is reserved to more complex cases that require lining repair (5). Although our nasal reconstruction with modified paramedian forehead flap had minor flap edge necrosis and contracture developed over the right alar, the major aims of the surgery were met. Further revision of the right alar region and continuing nasal dilatation is required for the long term.

## CONCLUSION

Forehead flap is the best method for the repair of extensive nasal defects. Extraordinary cosmetic and near-normal functional results can be achieved. However, this method requires patience and time. Careful use of forehead tissue expander has provided great benefit for short forehead patients.

**Informed Consent:** Informed consent for the patient has been obtained.

**Peer-Review:** Externally peer-reviewed.

**Author Contributions:** Conception/Design of Study- A.Z.M.S.; Data Acquisition- P.Y.; Data Analysis/Interpretation- P.Y., W.A.W.S., S.F.N.M.J.; Drafting Manuscript- P.Y.; Critical Revision of Manuscript- N.S.M.S., A.Z.M.S.; Final Approval and Accountability- N.S.M.S.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

## REFERENCES

1. Menick FJ – Nasal Reconstruction Art and Practice. New York: Mosby/Elsevier, 2009.
2. Menick FJ. Aesthetic refinements in use of forehead for nasal reconstruction: the paramedian forehead flap. Clin Plast Surg 1990;17(4):607-22.
3. Correa BJ, Weathers WM, Wolfswinkel EM, Thornton JF. The forehead flap: the gold standard of nasal soft tissue reconstruction. Semin Plast Surg 2013;27(2):96-103.
4. Boyd CM, Baker SR, Fader DJ, Wang TS, Johnson TM. The forehead flap for nasal reconstruction. Arch Dermatol 2000;136(11):1365-70.
5. Pochat VD, Oliveira FC, Mata FS, Cunha MS, Alonso N, Meneses JV. Preliminary stages before nasal reconstruction using forehead flap: restoring perinasal subunits and nostril patency. Plast Aesthet Res 2015;2:34-7.
6. Weng R, Li Q, Gu B, Liu K, Shen G, Xie F. Extended forehead skin expansion and single-stage nasal subunit plasty for nasal reconstruction. Plast Reconstr Surg 2010;125:1119-28.

**AIM AND SCOPE**

The Turkish Journal of Ear Nose and Throat (Tr-ENT) aims to contribute to the literature by publishing high quality original articles, case clinical reports, surgical techniques and invited reviews focusing on key subjects and contemporary developments in the field. The scope of the journal includes otology, neurootology, rhinology, head and neck, general ORL, facial plastic surgery and laryngology. The journal welcomes articles from other disciplines as well, provided that these are related to the major subject area. The target audience of the journal consists of academicians, researchers, professionals, students, related professional and academic bodies and institutions.

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Committee of Medical Journal Editors (ICMJE), World Association of Medical Editors (WAME), Council of Science Editors (CSE), Committee on Publication Ethics (COPE), European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal is in conformity with the Principles of Transparency and Best Practice in Scholarly Publishing ([doaj.org/bestpractice](https://doaj.org/bestpractice)).

The Turkish Journal of Ear Nose and Throat is currently indexed in TUBITAK ULAKBIM TR Index.

Processing and publication are free of charge with the journal. No fees are requested from the authors at any point throughout the evaluation and publication process.

All expenses of the journal are covered by the İstanbul University.

**INSTRUCTION TO AUTHORS**

The Turkish Journal of Ear Nose and Throat (Tr-ENT) is an international, scientific, open access and peer-reviewed publication of İstanbul University. It is published quarterly in March, June, September and December. The publication language of the journal is English. The journal started off in 1990 under the editorship of Professor Behbut Cevanşir. Since then it has been a significant source of knowledge in the field of otorhinolaryngology for researchers, residents and specialists. As of year 2018 Volume 28 Issue 1, the title of the journal was changed from "Kulak Burun Boğaz İhtisas Dergisi" (ISSN: 1300-7475, E-ISSN: 2147-67569) to "The Turkish Journal of Ear Nose and Throat" and the journal decided to publish articles only in English with a frequency of four issues per year. The Turkish Journal of Ear Nose and Throat aims to contribute to the literature by publishing high quality original articles, case reports, surgical techniques and invited reviews focusing on key subjects and contemporary developments in the field. The scope of the journal includes otology, neurootology, rhinology, head and neck, general ORL, facial plastic surgery and laryngology. The journal welcomes articles from other disciplines as well, provided that these are related to the major subject area. The target audience of the journal consists of academicians, researchers, professionals, students, related professional and academic bodies and institutions. Former title of the journal: Kulak Burun Boğaz İhtisas Dergisi (P-ISSN: 1300-7475 / E-ISSN: 2147-6756)

**POLICIES****Publication Policy**

The journal is committed to upholding the highest standards of publication ethics and pays regard to Principles of Transparency and Best Practice in Scholarly Publishing published by the Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the Open Access Scholarly Publishers Association (OASPA), and the World Association of Medical Editors (WAME) on <https://publicationethics.org/resources/guidelines-new/principles-transparency-and-best-practice-scholarly-publishing>

The subjects covered in the manuscripts submitted to the Journal for publication must be in accordance with the aim and scope of the Journal. Only those manuscripts approved by every individual author and that were not published before in or sent to another journal, are accepted for evaluation.

Changing the name of an author (omission, addition or order) in papers submitted to the Journal requires written permission of all declared authors.

Plagiarism, duplication, fraud authorship/denied authorship, research/data fabrication, salami slicing/salami publication, breaching of copyrights, prevailing conflict of interest are unethical behaviors. All manuscripts not in accordance with the accepted ethical standards will be removed from the publication. This also contains any possible malpractice discovered after the publication.

**Plagiarism**

Submitted manuscripts that pass preliminary control are scanned for plagiarism using iThenticate software. If plagiarism/self-plagiarism will be found authors will be informed. Editors may resubmit manuscript for similarity check at any peer-review or production stage if required. High similarity scores may lead to rejection of a manuscript before and even after acceptance.

Depending on the type of article and the percentage of similarity score taken from each article, the overall similarity score is generally expected to be less than 15 or 20%.

#### **Double Blind Peer-Review**

After plagiarism check, the eligible ones are evaluated by the editors-in-chief for their originality, methodology, the importance of the subject covered and compliance with the journal scope. The editor provides a fair double-blind peer review of the submitted articles and hands over the papers matching the formal rules to at least two national/international referees for evaluation and gives green light for publication upon modification by the authors in accordance with the referees' claims.

#### **Open Access Statement**

The journal is an open access journal and all content is freely available without charge to the user or his/her institution. Except for commercial purposes, users are allowed to read, download, copy, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

The open access articles in the journal are licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license. (<https://creativecommons.org/licenses/by-nc/4.0/deed.en>)

#### **Article Processing Charge**

All expenses of the journal are covered by the Istanbul University. Processing and publication are free of charge with the journal. There is no article processing charges or submission fees for any submitted or accepted articles.

#### **Copyright Notice**

Authors publishing with the journal retain the copyright to their work licensed under the Creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0) (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted, non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

### **ETHICS**

#### **Publication Ethics and Malpractice Statement**

The Turkish Journal of Ear Nose and Throat (Tr-ENT) is committed to upholding the highest standards of publication ethics and pays regard to Principles of Transparency and Best Practice in Scholarly Publishing published by the Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the Open Access Scholarly Publishers Association (OASPA), and the World Association of Medical Editors (WAME) on <https://publicationethics.org/resources/guidelines-new/principles-transparency-and-best-practice-scholarly-publishing>

All parties involved in the publishing process (Editors, Reviewers, Authors and Publishers) are expected to agree on the following ethical principles.

All submissions must be original, unpublished (including as full text in conference proceedings), and not under the review of any other publication synchronously. Authors must ensure that submitted work is original. They must certify that the manuscript has not previously been published elsewhere or is not currently being considered for publication elsewhere, in any language. Applicable copyright laws and conventions must be followed. Copyright material (e.g. tables, figures or extensive quotations) must be reproduced only with appropriate permission and acknowledgement. Any work or words of other authors, contributors, or sources must be appropriately credited and referenced.

Each manuscript is reviewed by at least two referees under double-blind peer review process. Plagiarism, duplication, fraud authorship/denied authorship, research/data fabrication, salami slicing/salami publication, breaching of copyrights, prevailing conflict of interest are unethical behaviors.

All manuscripts not in accordance with the accepted ethical standards will be removed from the publication. This also contains any possible malpractice discovered after the publication.

#### **Research Ethics**

The journal adheres to the highest standards in research ethics and follows the principles of international research ethics as defined below. The authors are responsible for the compliance of the manuscripts with the ethical rules.

- Principles of integrity, quality and transparency should be sustained in designing the research, reviewing the design and conducting the research.

- The research team and participants should be fully informed about the aim, methods, possible uses and requirements of the research and risks of participation in research.
- The confidentiality of the information provided by the research participants and the confidentiality of the respondents should be ensured. The research should be designed to protect the autonomy and dignity of the participants.
- Research participants should participate in the research voluntarily, not under any coercion.
- Any possible harm to participants must be avoided. The research should be planned in such a way that the participants are not at risk.
- The independence of research must be clear; and any conflict of interest or must be disclosed.
- In experimental studies with human subjects, written informed consent of the participants who decide to participate in the research must be obtained. In the case of children and those under wardship or with confirmed insanity, legal custodian's assent must be obtained.
- If the study is to be carried out in any institution or organization, approval must be obtained from this institution or organization.
- In studies with human subject, it must be noted in the method's section of the manuscript that the informed consent of the participants and ethics committee approval from the institution where the study has been conducted have been obtained.

#### **Ethics Committee Approval and Informed Consent**

The Turkish Journal of Ear Nose and Throat (Tr-ENT) takes as principle to comply with the ethical standards of World Medical Association (WMA) Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects revised in 2003 and WMA Statement on Animal Use in Biomedical Research revised in 2016.

An approval of research protocols by the Ethics Committee in accordance with international standards mentioned above is required for experimental, clinical, and drug studies and for some case reports. If required, ethics committee reports or an equivalent official document will be requested from the authors. For manuscripts concerning experimental research on humans, a statement should be included that shows that written informed consent of patients and volunteers was obtained following a detailed explanation of the procedures that they may undergo. For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. Information on patient consent, the name of the ethics committee, and the ethics committee approval number should also be stated in the Materials and Methods section of the manuscript. It is the authors' responsibility to carefully protect the patients' anonymity. For photographs that may reveal the identity of the patients, signed releases of the patient or of their legal representative should be enclosed.

#### **Author's Responsibilities**

It is authors' responsibility to ensure that the article is in accordance with scientific and ethical standards and rules. And authors must ensure that submitted work is original. They must certify that the manuscript has not previously been published elsewhere or is not currently being considered for publication elsewhere, in any language. Applicable copyright laws and conventions must be followed. Copyright material (e.g. tables, figures or extensive quotations) must be reproduced only with appropriate permission and acknowledgement. Any work or words of other authors, contributors, or sources must be appropriately credited and referenced.

All the authors of a submitted manuscript must have direct scientific and academic contribution to the manuscript. The author(s) of the original research articles is defined as a person who is significantly involved in "conceptualization and design of the study", "collecting the data", "analyzing the data", "writing the manuscript", "reviewing the manuscript with a critical perspective" and "planning/conducting the study of the manuscript and/or revising it". Fund raising, data collection or supervision of the research group are not sufficient roles to be accepted as an author. The author(s) must meet all these criteria described above. The order of names in the author list of an article must be a co-decision and it must be indicated in the Copyright Agreement Form. The individuals who do not meet the authorship criteria but contributed to the study must take place in the acknowledgement section. Individuals providing technical support, assisting writing, providing a general support, providing material or financial support are examples to be indicated in acknowledgement section.

All authors must disclose all issues concerning financial relationship, conflict of interest, and competing interest that may potentially influence the results of the research or scientific judgment.

When an author discovers a significant error or inaccuracy in his/her own published paper, it is the author's obligation to promptly cooperate with the Editor to provide retractions or corrections of mistakes.

#### **Responsibility for the Editor and Reviewers**

Editor-in-Chief evaluates manuscripts for their scientific content without regard to ethnic origin, gender, sexual orientation, citizenship, religious belief or political philosophy of the authors. He/She provides a fair double-blind peer review of the submitted articles for publication and ensures that all the information related to submitted manuscripts is kept as confidential before publishing.



Editor-in-Chief is responsible for the contents and overall quality of the publication. He/She must publish errata pages or make corrections when needed.

Editor-in-Chief does not allow any conflicts of interest between the authors, editors and reviewers. Only he has the full authority to assign a reviewer and is responsible for final decision for publication of the manuscripts in the Journal.

Reviewers must have no conflict of interest with respect to the research, the authors and/or the research funders. Their judgments must be objective.

Reviewers must ensure that all the information related to submitted manuscripts is kept as confidential and must report to the editor if they are aware of copyright infringement and plagiarism on the author's side.

A reviewer who feels unqualified to review the topic of a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process.

The editor informs the reviewers that the manuscripts are confidential information and that this is a privileged interaction. The reviewers and editorial board cannot discuss the manuscripts with other persons. The anonymity of the referees must be ensured. In particular situations, the editor may share the review of one reviewer with other reviewers to clarify a particular point.

## **PEER REVIEW**

### **Peer Review Policies**

Only those manuscripts approved by its every individual author and that were not published before in or sent to another journal, are accepted for evaluation.

Submitted manuscripts that pass preliminary control are scanned for plagiarism using iThenticate software. After plagiarism check, the eligible ones are evaluated by editor-in-chief for their originality, methodology, the importance of the subject covered and compliance with the journal scope.

The editor hands over the papers matching the formal rules to at least two national/international referees for double-blind peer review evaluation and gives green light for publication upon modification by the authors in accordance with the referees' claims.

### **Responsibility for the Editor and Reviewers**

Editor-in-Chief evaluates manuscripts for their scientific content without regard to ethnic origin, gender, citizenship, religious belief or political philosophy of the authors. Editor-in-Chief provides a fair double-blind peer review of the submitted articles for publication and ensures that all the information related to submitted manuscripts is kept as confidential before publishing.

Editor-in-Chief is responsible for the contents and overall quality of the publication. He/She must publish errata pages or make corrections when needed.

Editor-in-Chief does not allow any conflicts of interest between the authors, editors and reviewers. Only he has the full authority to assign a reviewer and is responsible for final decision for publication of the manuscripts in the Journal.

Reviewers must have no conflict of interest with respect to the research, the authors and/or the research funders. Their judgments must be objective.

Reviewers must ensure that all the information related to submitted manuscripts is kept as confidential and must report to the editor if they are aware of copyright infringement and plagiarism on the author's side.

A reviewer who feels unqualified to review the topic of a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process.

The editor informs the reviewers that the manuscripts are confidential information and that this is a privileged interaction. The reviewers and editorial board cannot discuss the manuscripts with other persons. The anonymity of the referees must be ensured. In particular situations, the editor may share the review of one reviewer with other reviewers to clarify a particular point.

### **Peer Review Process**

Only those manuscripts approved by its every individual author and that were not published before in or sent to another journal, are accepted for evaluation.

Submitted manuscripts that pass preliminary control are scanned for plagiarism using iThenticate software. After plagiarism check, the eligible ones are evaluated by Editor-in-Chief for their originality, methodology, the importance of the subject covered and compliance with the journal scope.

Editor-in-Chief evaluates manuscripts for their scientific content without regard to ethnic origin, gender, citizenship, religious belief or political philosophy of the authors and ensures a fair double-blind peer review of the selected manuscripts. The selected manuscripts are sent to at least two national/international referees for evaluation and publication decision is given by Editor-in-Chief upon modification by the authors in accordance with the referees' claims. Editor-in-Chief does not allow any conflicts of interest between the authors, editors and reviewers and is responsible for final decision for publication of the manuscripts in the Journal. Reviewers' judgments must be objective. Reviewers' comments on the following aspects are expected while conducting the review.

- Does the manuscript contain new and significant information?
- Does the abstract clearly and accurately describe the content of the manuscript?
- Is the problem significant and concisely stated?
- Are the methods described comprehensively?
- Are the interpretations and conclusions justified by the results?
- Is adequate references made to other Works in the field?
- Is the language acceptable?

Reviewers must ensure that all the information related to submitted manuscripts is kept as confidential and must report to the editor if they are aware of copyright infringement and plagiarism on the author's side.

A reviewer who feels unqualified to review the topic of a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process.

The editor informs the reviewers that the manuscripts are confidential information and that this is a privileged interaction. The reviewers and editorial board cannot discuss the manuscripts with other persons. The anonymity of the referees is important.

### **Manuscript Organization and Submission**

The manuscripts should be prepared in accordance with ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in December 2015 - <http://www.icmje.org/icmje-recommendations.pdf>). Author(s) are required to prepare manuscripts in accordance with the CONSORT guidelines for randomized research studies, STROBE guidelines for observational original research studies, STARD guidelines for studies on diagnostic accuracy, PRISMA guidelines for systematic reviews and meta-analysis, ARRIVE guidelines for experimental animal studies, and TREND guidelines for non-randomized public behavior.

Manuscripts can only be submitted through the journal's online manuscript submission and evaluation system, available at <https://dergipark.org.tr/tr/journal/3565/submission/step/manuscript/new> Manuscripts submitted via any other medium will not be evaluated.

Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal's guidelines. Submissions that do not conform to the journal's guidelines will be returned to the submitting author with technical correction requests.

Author(s) are required to submit the following documents together with the manuscript and must ensure that the abstract and keywords are in line with the standards explained in below.

- **Copyright Agreement Form**
- **Author Form and ICMJE Potential Conflict of Interest Disclosure Form**
- **Ethics Committee Approval**
- **Cover Letter to the Editor**
- **Title Page:** A separate title page should be submitted with all submissions and this page should include:
  - The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
  - Name(s), affiliations, academic degree(s) and ORCID ID(s) of the author(s),
  - Grant information and detailed information on the other sources of support,
  - Name, address, telephone (including the mobile phone number) and fax numbers, and email address of the corresponding author,
  - Acknowledgment of the individuals who contributed to the preparation of the manuscript but who do not fulfil the authorship criteria.

**Abstract:** Abstract should be submitted with all submissions except for Letters to the Editor. The abstract of Original Articles should be structured with subheadings (Objective, Materials and Methods, Results, and Conclusion). Abstracts of Case Reports and Reviews should be unstructured. Abstracts should be 200-250 words.

**Keywords:** Each submission must be accompanied by a minimum of 3 to a maximum of 6 keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (<http://www.nlm.nih.gov/mesh/MBrowser.html>) .

### Manuscript Types

**Original Articles:** This is the most important type of article since it provides new information based on original research. The main text of original articles should be structured with Introduction, Material and Method, Results, Discussion, and Conclusion subheadings..

Statistical analysis to support conclusions is usually necessary. Statistical analyses must be conducted in accordance with international statistical reporting standards (Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. *Br Med J* 1983; 7; 1489-93). Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used during the process must be specified.

Units should be prepared in accordance with the International System of Units (SI).

**Invited Review Articles:** Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed. These authors may even be invited by the journal. Reviews should describe, discuss, and evaluate the current level of knowledge of a topic in clinical practice and should guide future studies. The main text should contain Introduction, Clinical and Research Consequences, and Conclusion sections. Please check Table 1 for the limitations for Review Articles.

**Case Reports:** There is limited space for case reports in the journal and reports on rare cases or conditions that constitute challenges in diagnosis and treatment, those offering new therapies or revealing knowledge not included in the literature, and interesting and educative case reports are accepted for publication. The text should include Introduction, Case Presentation, Discussion, and Conclusion subheadings. Please check Table 1 for the limitations for Case Reports.

**Letters to the Editor:** This type of manuscript discusses important parts, overlooked aspects, or lacking parts of a previously published article. Articles on subjects within the scope of the journal that might attract the readers' attention, particularly educative cases, may also be submitted in the form of a "Letter to the Editor." Readers can also present their comments on the published manuscripts in the form of a "Letter to the Editor." Abstract, Keywords, and Tables, Figures, Images, and other media should not be included. The text should be unstructured. The manuscript that is being commented on must be properly cited within this manuscript.

### Tables

Tables should be included in the main document, presented after the reference list, and they should be numbered consecutively in the order they are referred to within the main text. A descriptive title must be placed above the tables. Abbreviations used in the tables should be defined below the tables by footnotes (even if they are defined within the main text). Tables should be created using the "insert table" command of the word processing software and they should be arranged clearly to provide easy reading. Data presented in the tables should not be a repetition of the data presented within the main text but should be supporting the main text.

### Figures and Figure Legends

Figures, graphics, and photographs should be submitted as separate files (in TIFF or JPEG format) through the submission system. The files should not be embedded in a Word document or the main document. When there are figure subunits, the subunits should not be merged to form a single image. Each subunit should be submitted separately through the submission system. Images should not be labeled (a, b, c, etc.) to indicate figure subunits. Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends. Like the rest of the submission, the figures too should be blind. Any information within the images that may indicate an individual or institution should be blinded. The minimum resolution of each submitted figure should be 300 DPI. To prevent delays in the evaluation process, all submitted figures should be clear in resolution and large in size (minimum dimensions: 100 × 100 mm). Figure legends should be listed at the end of the main document.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition.

When a drug, product, hardware, or software program is mentioned within the main text, product information, including the name of the product, the producer of the product, and city and the country of the company (including the state if in USA), should be provided in parentheses in the following format: "Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)"

All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively in the order they are referred to within the main text.

Limitations, drawbacks, and the shortcomings of original articles should be mentioned in the Discussion section before the conclusion paragraph.

### Revisions

When submitting a revised version of a paper, the author must submit a detailed "Response to the reviewers" that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer's comment, followed by the author's reply and line numbers where the changes have been made) as well as an annotated copy of the main document. Revised manuscripts must be submitted within 30 days from the date of the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request this extension before the initial 30-day period is over. Accepted manuscripts are copy-edited for grammar, punctuation, and format. Once the publication process of a manuscript is completed, it is published online on the journal's webpage as an ahead-of-print publication before it is included in its scheduled issue. A PDF proof of the accepted manuscript is sent to the corresponding author and their publication approval is requested within two days of their receipt of the proof. The latest status of the submitted manuscripts and other information about the journal can be accessed at <http://tr-ent.com>. The editorial and publication processes of the journal are conducted in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing ([doaj.org/bestpractice](http://doaj.org/bestpractice)). An ORCID ID is required for all authors during the submission of the manuscript. The ID is available at <http://orcid.org> with free of charge.

### Reference Style and Examples

Authors are responsible for supply complete and correct references. References should be numbered according to the order used in the text. Numbers should be given in brackets and placed at the end of the sentence. Examples are given below on the use of references. Reference end note style Vancouver

**Periodicals:** Author(s) Last Name initial(s) name of author(s) (if there are six or fewer authors, all authors should be written; if the number of authors are seven or more, only the first six of the authors should be written and the rest as "et al"). The title of the article, the abbreviated name of the journal according to the Index Medicus, Year; Volume (Issue): The first and last page numbers.

**Example:** Robson A, Greene J, Ansari N, Kim B. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. *The American Journal of Surgical Pathology* 2001;25:710-20. Books: Surname of the author(s) initial name(s) of author(s). The name of the book. The edition number. Place of publication: Publisher, Publication year.

**Book chapters:** The author (s) surname of the chapter initial (s) letter of the name. Section title. In: Surname of editor (s) initial (s) letter of first name (s) ed / eds. The name of the book. Edition number. Place of publication: Publisher, year of publication: The first and last page numbers of the chapter. Web address: If a "web" address is used as the reference address, the web address date should be given in brackets with the address. The DOI (Digital Object Identifier) number must be provided, when a web access article used in the text as a reference.

**Example:** AB Author, CD Author. Title of document. Retrieved from <http://Web address> (Accession date: aa/bb/2016).

### Congress papers:

**Thesis:** Maden KL. Experimental investigation of the ..... Master Thesis, Health Science Institute of Ankara University, Ankara, 2005.

**SUBMISSION CHECKLIST**

- Cover letter to the editor
  - The category of the manuscript
  - Confirming that “the paper is not under consideration for publication in another journal”.
  - Including disclosure of any commercial or financial involvement.
  - Confirming that the statistical design of the research article is reviewed.
  - Confirming that last control for fluent English was done.
  - Confirming that journal policies detailed in Information for Authors have been reviewed.
  - Confirming that the references cited in the text and listed in the references section are in line with NLM.
- Copyright Agreement Form
- Author Form
- Permission of previous published material if used in the present manuscript
- Acknowledgement of the study “in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration.
- Statement that informed consent was obtained after the procedure(s) had been fully explained. Indicating whether the institutional and national guide for the care and use of laboratory animals was followed as in “Guide for the Care and Use of Laboratory Animals”.
- Title page
  - The category of the manuscript
  - The title of the manuscript
  - Short title (running head)
  - All authors’ names and affiliations (institution, faculty/department, city, country), e-mail addresses
  - Corresponding author’s email address, full postal address, telephone and fax number
  - ORCIDs of all authors.
- Main Manuscript Document
  - The title of the manuscript
  - Abstract 200-250 words
  - Key words: 3 - 6 words
  - Main article sections
  - References
  - Acknowledgement (if exists)
  - All tables, illustrations (figures) (including title, description, footnotes)

**Editor:** İsmet Aslan

**Address:** Istanbul University, Istanbul Faculty of  
Medicine Deanery, Turgut Özal Cad. 34093, Çapa,  
Fatih, Istanbul, Turkey

**Phone:** +90 212 414 21 61

**E-mail:** tr-ent@istanbul.edu.tr

**Publisher:** Istanbul University Press

**Address:** İstanbul Üniversitesi Merkez Kampüsü,  
34452 Beyazıt, Fatih / Istanbul, Turkey

**Phone:** +90 212 440 00 00